On this page
Quick Reference
Overview and Recommendations
Background
- •Define meningitis as the acute or chronic inflammation of the protective membranes surrounding the brain and spinal cord, specifically the leptomeninges. It is a critical global health challenge with significant geographic heterogeneity, such as the high burden seen in the African Meningitis Belt.
- •Identify the primary infectious etiologies, which vary by age and risk factors: and dominate adult bacterial cases, while is the leading cause in neonates. Viral or 'aseptic' meningitis is most frequently caused by and is generally less severe but more common.
- •Recognize the high morbidity associated with the condition, as more than 30% of survivors worldwide suffer from long-term neurological sequelae, including sensorineural hearing loss (SNHL), cognitive impairment, and seizure disorders.
- •Distinguish between acute (hours to days) and chronic (more than 4 weeks) forms. Tuberculous meningitis (TBM) and cryptococcal meningitis often present subacutely and are major causes of mortality in immunocompromised populations, particularly those with HIV/AIDS.
- •Consider non-infectious triggers such as drug-induced aseptic meningitis (DIAM)—often linked to NSAIDs or antibiotics—and systemic autoinflammatory diseases like (NPSLE) or GFAP astrocytopathy.
Evaluation
- •Suspect meningitis in any patient presenting with fever, severe headache, and nuchal rigidity (neck stiffness), though be aware that this 'classic triad' is present in less than half of confirmed cases. In neonates, look for non-specific signs like irritability, poor feeding, bulging fontanelles, or hypothermia (Temperature ≤ 36.0°C).
- •Perform a targeted physical exam for meningeal irritation using Kernig’s sign (resistance to knee extension with the hip flexed) and Brudzinski’s sign (involuntary hip flexion during passive neck flexion). Utilize the jolt accentuation of headache—increasing pain with rapid horizontal head rotation—as it is a highly sensitive sign for meningeal inflammation.
- •Assess for 'red flags' that indicate high-risk complications, such as rapidly progressive purpura (suggestive of meningococcemia), focal neurological deficits, papilledema, or a Glasgow Coma Scale (GCS) score < 12.
- •Order a non-contrast CT prior to performing a lumbar puncture (LP) only if specific contraindications are present: focal neurological deficits, new-onset seizures, papilledema, or known immunocompromise. Do not delay the first dose of antibiotics for imaging if an LP is deferred.
- •Obtain blood cultures and a simultaneous serum glucose level immediately upon arrival. Blood cultures are positive in 50-80% of patients with bacterial meningitis and may provide a diagnosis if the LP is 'dry' or contraindicated.
- •Perform a lumbar puncture to analyze cerebrospinal fluid (CSF) for opening pressure, cell count with differential, glucose, and protein. Typical bacterial findings include neutrophilic pleocytosis (>5 cells/μL), elevated protein, and a CSF/serum glucose ratio < 0.4.
- •Utilize rapid molecular diagnostics such as the Meningitis/Encephalitis panel, which can identify 14 common pathogens via multiplex PCR within approximately one hour, significantly improving time-to-targeted-therapy.
- •Evaluate for (TBM) in patients with subacute symptoms or high-risk backgrounds using CSF biomarkers (IFN-γ, IL-6) and molecular tools like CBNAAT or Loop-mediated isothermal amplification (LAMP), which has a sensitivity of ~62.5% in pediatric populations.
- •Screen for cryptococcal antigen (CrAg) in all HIV-positive patients with a CD4 count < 100 cells/μL, as high blood CrAg titers are strongly predictive of concurrent meningitis and increased mortality.
- •Rule out mimics such as (via CT or presence of xanthochromia in CSF) and autoimmune encephalitis (via MRI findings like linear perivascular radial enhancement in GFAP astrocytopathy).
Management
- •Administer empiric antimicrobial therapy within 60 minutes of patient arrival; every hour of delay is associated with increased mortality. For most adults, initiate Ceftriaxone 2 g IV every 12 hours and Vancomycin 15-20 mg/kg IV every 8-12 hours.
- •Add Ampicillin 2 g IV every 4 hours to the empiric regimen for patients over age 50, pregnant individuals, or those with immunocompromise to provide coverage for Listeria monocytogenes.
- •Administer adjunctive Dexamethasone 0.15 mg/kg IV every 6 hours (maximum 10 mg) starting 10-20 minutes before or concurrently with the first dose of antibiotics to reduce the risk of hearing loss and neurological sequelae in bacterial cases.
- •Continue dexamethasone for 4 days in patients confirmed to have Streptococcus pneumoniae meningitis; discontinue if the pathogen is found to be viral or a different bacterium where steroid benefit is less clear.
- •Manage (TBM) with a standard 4-drug regimen (Rifampin, Isoniazid, Pyrazinamide, and Ethambutol) plus adjunctive dexamethasone for 6-8 weeks. Consider high-dose Rifampin 35 mg/kg/day to improve CNS penetration, though its mortality benefit is still debated.
- •Treat HIV-associated cryptococcal meningitis using the AMBITION protocol: a single high dose of Liposomal Amphotericin B 10 mg/kg on Day 1, followed by 14 days of oral Flucytosine 100 mg/kg/day and Fluconazole 1200 mg/day.
- •Monitor and manage increased intracranial pressure (ICP) using head elevation to 30 degrees and osmotic therapy (Mannitol 0.5-1.0 g/kg). Consider external ventricular drainage (EVD) for patients with refractory hypertension or symptomatic hydrocephalus.
- •Implement seizure precautions and treat active seizures with benzodiazepines (e.g., Lorazepam 0.1 mg/kg IV), followed by maintenance anticonvulsants like Levetiracetam if cortical involvement is suspected.
- •Provide post-exposure prophylaxis (PEP) to close contacts of patients with N. meningitidis or H. influenzae type b using Ciprofloxacin 500 mg PO (single dose) or Rifampin 600 mg PO twice daily for 2 days.
- •Perform formal audiological diagnostic testing at the time of discharge or within 4 weeks of recovery to detect sensorineural hearing loss (SNHL), as early intervention is critical for preventing cognitive decline.
- •Avoid the use of adjunctive corticosteroids in HIV-positive adults with TBM, as trials have shown they may not provide the same survival benefit as seen in HIV-negative populations.
- •Refer to neurosurgery immediately if imaging reveals a (complicating ~1.9% of bacterial cases) or if there is evidence of obstructive hydrocephalus requiring a shunt.
Board Review — High Yield
- •Jolt accentuation — The most sensitive physical exam maneuver for identifying meningeal irritation (worsening headache with horizontal head rotation).
- •CSF/Serum Glucose Ratio < 0.4 — A classic laboratory finding strongly suggestive of bacterial, fungal, or tuberculous meningitis over viral causes.
- •Waterhouse-Friderichsen syndrome — Adrenal insufficiency caused by bilateral adrenal hemorrhage, a catastrophic complication of meningococcemia.
- •LTA4H genotype — A genetic marker that predicts whether a patient with tuberculous meningitis will benefit from adjunctive corticosteroids.
- •AMBITION-cm Trial — Validated a single high-dose of liposomal amphotericin B as part of an effective, less toxic induction regimen for cryptococcal meningitis.
- •Sensorineural hearing loss — The most common long-term sequela of bacterial meningitis, necessitating audiological follow-up for all survivors.
- •Dexamethasone timing — Must be given before or with the first dose of antibiotics to be effective in reducing inflammatory neurological damage.
- •Enterovirus — The most common cause of 'aseptic' meningitis, typically presenting with a benign, self-limiting course.
Deep Dive — Evidence Details
Definition, Synonyms, and Classification
- ▸Meningitis is an inflammatory meningeal and CSF syndrome that may occur alone or with encephalitis.[269][271][274][276]
- ▸Aseptic meningitis indicates absence of demonstrated bacterial infection, not necessarily absence of infection.[9][11]
- ▸Probable meningitis may be diagnosed with meningitis-consistent CSF abnormalities despite negative culture, including culture-negative CSF with pleocytosis and neutrophil predominance in a neonatal sepsis study.[271]
- ▸Major etiological classes represented in the evidence are bacterial, viral, mycobacterial, fungal, and parasitic meningitis.[3][8][9][10][11][12][269][270][271][272][274][275][276]
- ▸Subarachnoid neurocysticercosis is a compartment-specific parasitic form defined by pathology, characteristic cyst location, serology or Del Brutto criteria, or inflammatory CSF with positive parasite testing and exclusion of other pathogens.[269]
Definition
Meningitis is an inflammatory syndrome involving the meninges and cerebrospinal fluid (CSF), identified clinically and/or through CSF abnormalities; the available evidence includes infectious disease presentations ranging from isolated meningitis to meningoencephalitis and meningomyelitis.[269]C[271][274][276]C In practice, the term may describe disease caused by bacteria, viruses, fungi, mycobacteria, parasites, or less commonly other infectious agents.[3][6]C[8]C[9]C[10]C[11]C[12]C[274][275]C[276]C “Aseptic meningitis” generally denotes meningitis without a demonstrated bacterial cause; however, the term does not imply a noninfectious origin, because enteroviruses and lymphocytic choriomeningitis virus have been associated with aseptic meningitis.[9]C[11]C
Meningitis should be distinguished conceptually from encephalitis, although the two may coexist. The term meningoencephalitis is appropriate when meningeal inflammation occurs with brain inflammation, as described for West Nile virus, bat reovirus, pigeon paramyxovirus type 1, and Angiostrongylus cantonensis infection.[6]C[12]C[276]C[278]C Neurolisteriosis may also present as central nervous system infection, including meningitis or meningoencephalitis, whereas listeriosis cohorts separately classify bacteremia, neurolisteriosis, perinatal infection, and other disease.[275]C
Synonyms and related terms
Common clinical descriptors include acute meningitis, bacterial meningitis, viral or aseptic meningitis, tuberculous meningitis, cryptococcal meningitis, meningococcal meningitis, neonatal meningitis, and neurocysticercal meningitis.[3][8]C[9]C[10]C[11]C[269]C[270][271][274][275]C These labels may refer to the suspected cause, epidemiological setting, age group, or anatomical compartment rather than to different inflammatory processes.[269]C[270][271][274]
“Probable meningitis” is an operational term used when CSF findings are consistent with meningitis but culture confirmation is absent. In very preterm and/or very-low-birth-weight infants with early-onset sepsis, this designation required culture-negative CSF with pleocytosis and neutrophil predominance, together with other meningitis-consistent abnormalities reported in the study definition.[271] This category is distinct from culture-confirmed bacterial meningitis and illustrates that meningitis classification may remain clinical or laboratory-based when microbiological confirmation is unavailable.[271]
“Neuroborreliosis” or Lyme neuroborreliosis refers to neurological infection associated with Borrelia burgdorferi; patients evaluated for suspected disease may have neurological manifestations and positive two-tier serology, but diagnosis incorporates lumbar-puncture findings and a formal European case definition.[277]C Thus, positive serum antibodies alone should not be treated as synonymous with Lyme meningitis.[277]C
Classification by aetiology
Bacterial meningitis
Bacterial meningitis includes disease caused by organisms such as Neisseria meningitidis, Escherichia coli, and Listeria monocytogenes.[8]C[10]C[272][275]C N. meningitidis remains associated with invasive meningococcal disease and meningitis, while genomic surveillance has also identified urogenital disease and imported serogroup W, sequence type 11, clonal complex 11 infections among travellers returning from Saudi Arabia.[8]C[10]C In neonatal invasive disease, E. coli is an important cause of bloodstream and CSF infection; longitudinal surveillance specifically examined the historical assumption that K1-capsule-positive strains dominate these infections.[272] Listeriosis may involve the nervous system, with neurolisteriosis representing a clinically distinct manifestation within broader confirmed listeriosis cohorts.[275]C
Viral meningitis
Viral meningitis includes enterovirus-associated disease, parechovirus-A infection, lymphocytic choriomeningitis virus infection, and arboviral disease such as West Nile virus infection.[9]C[11]C[274][276]C A recombinant echovirus 6/coxsackievirus B1 enterovirus caused an aseptic meningitis cluster involving a daycare teacher and children, demonstrating that genetically recombinant enteroviruses can produce meningitis-associated outbreaks.[11]C Parechovirus-A3 was investigated in febrile neonates and infants younger than 4 months hospitalized with suspected sepsis, meningitis, and/or encephalitis, using serum and/or CSF PCR and sequencing.[274] LCMV is a recognized cause of aseptic meningitis and can cause severe disease after exposure to aerosolized excreta from infected house mice; severe illness can occur even in an immunocompetent person.[9]C West Nile virus may produce neuroinvasive disease with meningoencephalitis, particularly in older adults; a 2024 Turkish outbreak cohort had a mean age of 63.3 years.[276]C
Mycobacterial and fungal meningitis
Tuberculous meningitis (TBM) is the most severe clinical manifestation of tuberculosis and may be classified as definite, probable, or possible according to a uniform case definition.[3] In a Thai adult cohort, 32.7% of patients had definite TBM, 23.0% probable TBM, and 44.2% possible TBM, illustrating the importance of graded diagnostic certainty.[3] Cryptococcal meningitis is an opportunistic disease particularly relevant to advanced HIV disease; optimized care models therefore incorporate enhanced CD4 testing and cryptococcal-antigen screening among patients with advanced HIV disease.[270]
Parasitic and compartment-specific meningitis
Parasitic meningitis includes subarachnoid neurocysticercosis caused by Taenia solium and eosinophilic meningoencephalitis caused by Angiostrongylus cantonensis.[12]C[269]C Subarachnoid neurocysticercosis is defined by histopathology; cysts in the basilar subarachnoid spaces, Sylvian fissures, or spinal subarachnoid spaces with T. solium antibody positivity or fulfillment of Del Brutto criteria; or inflammatory CSF with T. solium antigen or quantitative PCR positivity and negative testing for viral, fungal, and bacterial causes.[269]C This anatomical classification emphasizes that meningitis may be categorized by the meningeal compartment involved as well as by pathogen.[269]C
Classification by age, setting, and associated pathology
Meningitis may be classified as neonatal or infant disease, including early-onset sepsis-associated meningitis and parechovirus infection; as adult disease, including TBM and West Nile neuroinvasive disease; or as disease associated with advanced HIV and opportunistic infection.[270][271][274][276]C It may also be categorized as community-associated, outbreak-associated, travel-associated, zoonotic, or procedure/anatomy-associated. Examples include daycare-associated enterovirus transmission, household exposure concerns in invasive group A streptococcal disease, travel-associated serogroup W meningococcal disease, rodent-associated LCMV, mosquito-associated West Nile virus, bat-associated reovirus, avian-associated pigeon paramyxovirus type 1, and meningitis risk arising from a skull-base CSF leak.[6]C[9]C[10]C[11]C[273]C[276]C[278]C[279]C These epidemiological labels supplement, but do not replace, classification by clinical syndrome, CSF findings, microbiology, and anatomical distribution.[269]C[271][277]C[279]C
| Classification axis | Examples supported by the evidence |
|---|---|
| Clinical syndrome | Meningitis; aseptic meningitis; meningoencephalitis; meningomyelitis-related disease [6]C[9]C[11]C[12]C[269]C[276]C[278]C |
| Aetiology | Bacterial, viral, mycobacterial, fungal, parasitic [3][8]C[9]C[10]C[11]C[12]C[269]C[270][274][275]C[276]C |
| Diagnostic certainty | Confirmed, probable, possible, or operationally probable meningitis [3][271][277]C |
| Age or host context | Neonates/young infants, adults, advanced HIV disease, immunocompetent hosts [9]C[270][271][274][276]C |
| Epidemiology or anatomy | Outbreak-associated, travel-associated, zoonotic, CSF-leak-associated, or subarachnoid disease [9]C[10]C[11]C[269]C[273]C[276]C[278]C[279]C |
Epidemiology and Risk Factors
- ▸In a Danish population-based pediatric cohort, bacterial meningitis incidence was **24 per 1,000,000 children annually**. [346]
- ▸Meningococcal disease burden was substantially higher during epidemics than in endemic settings, with reported prevalence of **12.1% versus 0.76%** and case-fatality ratios of **12.8% versus 3.0%**. [287]
- ▸Infancy, particularly the first **90 days**, is an important risk period for invasive bacterial infection and GBS meningitis. [282][359]
- ▸CSF leakage, meningeal breach, cochlear implantation, and post-neurosurgical status are important structural or healthcare-associated risk contexts. [51][288]
- ▸TBM is associated with severe neurological complications, including cerebral infarction; HIV-related neurological disease and nusinersen exposure are additional relevant contexts. [156][284][360]
Global and population-based epidemiology
Meningitis epidemiology varies substantially by age, organism, geography, vaccination coverage, and healthcare access. In a population-based cohort of previously healthy Danish children aged 0–17 years, the annual incidence of microbiologically verified central nervous system infection was 125 per 1,000,000 children; viral infections accounted for 49 per 1,000,000 and bacterial meningitis for 24 per 1,000,000. [346] These figures describe a high-income, population-based setting and should not be generalized to regions with different surveillance systems or disease burdens. [346]
Invasive meningococcal disease remains an important cause of epidemic and sporadic meningitis in India. A 2026 expert consensus reported a prevalence of 12.1% during epidemics and 0.76% in endemic settings, with case-fatality ratios of 12.8% and 3.0%, respectively; the authors emphasized that weak surveillance probably underestimates the true burden. [287] Serogroup A has historically predominated in India, while serogroups C, W, and Y are emerging. [287] The reported age distribution is bimodal, with the greatest burden in children younger than 5 years and in adolescents; 61.8% of reported invasive meningococcal disease occurred in children younger than 5 years in the summarized evidence. [287]
Age-related risk
Young infants are a high-risk group for invasive bacterial infection, including meningitis. A systematic review of previously healthy, well-appearing febrile infants aged 60–90 days evaluated the prevalence of invasive bacterial infection, defined as bacteremia or bacterial meningitis, across emergency and outpatient settings. [282] The supplied abstract does not provide the pooled prevalence estimate; therefore, the evidence supports heightened epidemiological attention to this age group but does not establish a single universal risk percentage from the available data. [282]
Group B Streptococcus (GBS) is an important cause of disease in young infants. In a prospective Dutch multicentre cohort from 2018–2024, 375 infants aged 0–89 days had culture-confirmed GBS sepsis or meningitis; 57% had early-onset disease at 0–6 days and 43% had late-onset disease at 7–89 days. [359] Overall, 21% had definitive meningitis, 55% had sepsis without definitive meningitis, and 24% had probable meningitis. [359] These findings identify both the neonatal period and the remainder of the first 3 months of life as clinically relevant risk windows for GBS disease. [359]
Structural and healthcare-associated risk factors
Cerebrospinal-fluid leakage and cochlear implantation are recognized risk factors for bacterial meningitis because they create or reflect a breach in normal meningeal barriers. [51]D In a French nationwide prospective cohort of children older than 3 months, 251 of 5,879 bacterial meningitis cases (4.3%) occurred in children with known CSF leakage, including meningeal breach or cochlear implantation. [51]D This population represents a selected subgroup rather than the risk among all children with CSF leakage, and the study specifically examined the effect of PCV13 in this population. [51]D
Neurosurgical exposure is another epidemiologically important context for pediatric bacterial meningitis. A seven-year study from Southwest China analyzed 258 children with culture-positive bacterial meningitis and specifically assessed post-neurosurgical cases, pathogen distribution, antimicrobial resistance, refractory disease, and intensive-care admission. [288] The abstract indicates that pathogen spectrum and resistance patterns were region-specific and dynamic, limiting direct extrapolation to other healthcare systems. [288]
Tuberculous meningitis and HIV-associated risk
Tuberculous meningitis (TBM) is a severe extrapulmonary manifestation of tuberculosis with substantial mortality and long-term neurological morbidity. [31][283] The supplied evidence focuses primarily on treatment rather than population incidence or host acquisition risk: a meta-analysis included 7 randomized trials and 1,296 patients, while a network meta-analysis included 29 randomized trials and 4,640 patients. [31][286] These studies therefore inform therapeutic evidence, not the community prevalence of TBM or the probability of progression from tuberculosis infection to meningitis. [31][286]
Cerebral infarction is a frequent and serious complication of TBM. [156] A secondary analysis of the ACT-TBM randomized trial included 237 patients and examined infarct patterns, associated factors, and predictors, but the supplied abstract does not provide the final predictor estimates. [156] HIV infection is also associated with neurological complications, including potentially infectious central nervous system disease; a Cameroonian retrospective cohort evaluated prevalence and mortality among people living with HIV who developed HIV-related neurological complications between 2016 and 2023. [284] The available abstract does not report the specific meningitis proportion or adjusted risk estimates. [284]
Drug-related and noninfectious meningitis
Meningitis is not exclusively infectious. Rare drug-induced noninfectious meningitis has been reported during treatment of spinal muscular atrophy with nusinersen. [360] A WHO pharmacovigilance analysis identified 73 individual case safety reports and examined disproportionality, timing of onset, and possible risk factors; diagnosis generally requires exclusion of infectious and other causes, and the time to onset is highly variable. [360]
Interpretation of risk
Risk estimates should be interpreted in context because the available studies differ in design, case ascertainment, age range, geography, and diagnostic criteria. [282][346][359] The most consistently supported risk settings in the supplied evidence are young infancy, exposure to GBS, meningococcal transmission during epidemics, CSF leakage or cochlear implantation, post-neurosurgical care, immunocompromised states such as HIV, and exposure to nusinersen for noninfectious meningitis. [51]D[284][287][288][359][360]
| Population or setting | Evidence |\n|---|---|\n| Danish children aged 0–17 years | Annual incidence: 125 per 1,000,000 for verified CNS infection; 24 per 1,000,000 for bacterial meningitis. [346] |\n| Indian meningococcal disease | Reported prevalence: 12.1% in epidemics and 0.76% in endemic settings; CFR: 12.8% and 3.0%, respectively. [287] |\n| Infants aged 0–89 days with GBS disease in the Netherlands | 375 cases; 57% early-onset and 43% late-onset disease; 21% definitive meningitis. [359] |\n| Children with CSF leakage or cochlear implant in France | 251 of 5,879 pediatric bacterial meningitis cases (4.3%). [51]D |\n| Nusinersen pharmacovigilance reports | 73 reports of possible drug-induced noninfectious meningitis. [360] |
Etiology and Triggering Factors
- ▸Documented etiologies include bacterial, viral, fungal, tuberculous, zoonotic, congenital, postoperative, and post-neurosurgical meningitis. [294][295][296][301][304][307][309]
- ▸Febrile infants aged ≤90 days are a key high-risk population for invasive bacterial infection, defined in the cited reviews as bacteremia or bacterial meningitis. [293][282]
- ▸PCV13 reduced vaccine-serotype pneumococcal disease in Taiwan, but non-vaccine serotypes remain an increasing concern. [297]
- ▸Recent neurosurgery, posterior fossa tumor surgery, immunosuppression, HIV, geographic exposure to Coccidioides, and tropical zoonotic exposure to Leptospira are important contextual triggers. [295][296][301][304][309]
- ▸A negative multiplex meningitis–encephalitis panel does not exclude infection when the panel lacks the causative organism. [306]
Overview
Meningitis is etiologically heterogeneous and may result from bacterial, viral, fungal, mycobacterial, zoonotic, or noninfectious inflammatory processes. The supplied evidence particularly documents bacterial meningitis, tuberculous meningitis, coccidioidal meningitis, cryptococcal meningitis, leptospiral meningitis, congenital lymphocytic choriomeningitis virus (LCMV) infection, and postoperative or post-neurosurgical meningitis. [294][295]C[296][297]C[301][304][307]C[309]
The likely cause is influenced by age, immune status, geographic exposure, vaccination history, recent neurosurgery, and healthcare-associated exposures. In febrile infants, invasive bacterial infection (IBI) is defined in the cited literature as bacteremia or bacterial meningitis; systematic reviews have specifically evaluated infants aged up to 90 days, including a separate assessment of previously healthy, well-appearing infants aged 60–90 days. [293][282]
Bacterial meningitis
Bacterial meningitis may occur in young infants, children, and adults. In pediatric disease, the causative spectrum and antimicrobial-resistance patterns vary by region and over time. A seven-year study from Southwest China analyzed culture-positive pediatric bacterial meningitis and specifically emphasized differences between community-acquired disease and post-neurosurgical cases, demonstrating that local epidemiology is important when considering likely pathogens and empirical therapy. [288]
Streptococcus pneumoniae remains a major cause of bacterial meningitis. Following implementation of the 13-valent pneumococcal conjugate vaccine (PCV13) in Taiwan, vaccine-serotype invasive disease declined, while non-vaccine serotypes became an increasing concern; therefore, vaccination reduces—but does not eliminate—the risk of pneumococcal meningitis and may alter the circulating serotype distribution. [297]C
Healthcare-associated bacterial meningitis can follow neurosurgical procedures. Pediatric posterior fossa tumor surgery is a documented setting for postoperative meningitis, and postoperative cases may be culture-positive or culture-negative. [301] Post-neurosurgical bacterial meningitis is also reported after neurosurgical intensive-care treatment, where early recognition is difficult and diagnostic prediction models have been developed. [304] Rarely, invasive exposure to traditional procedures may precede infection: one reported patient developed Escherichia coli meningitis after cupping and acupuncture, although this represents case-report evidence rather than an established population-level risk estimate. [305]C
Spontaneous Gram-negative bacillary meningitis is rare in adults and is associated with particularly severe illness in older patients with substantial comorbidity. Proteus mirabilis meningitis may be missed by a limited multiplex meningitis–encephalitis panel despite cerebrospinal-fluid findings strongly suggestive of bacterial infection, illustrating that the apparent pathogen profile depends partly on test coverage. [306]C
Viral and congenital infections
LCMV is a congenital viral cause of neurologic disease. Reported congenital infection has been associated with chorioretinitis, cerebral ventriculomegaly, major neurologic malformations, placental vascular or other placental pathology, and fetal demise. [307]C In suspected congenital LCMV infection, the cited report recommends assessment for chorioretinitis, LCMV antibodies, and placental evidence of infection. [307]C
Fungal and mycobacterial meningitis
Coccidioidal meningitis is a manifestation of disseminated coccidioidomycosis, a fungal infection endemic to the southwestern United States. Hospitalization data from Texas identified substantial effects in western Texas and metropolitan areas, supporting geographic exposure as an important epidemiologic trigger. [296] Coccidioidal meningitis occurs in approximately 1% of coccidioidomycosis cases in the cited study and may lead to hydrocephalus requiring shunting and lifelong antifungal therapy. [308]
Cryptococcus neoformans is an opportunistic fungal pathogen and a leading cause of HIV-associated meningitis, particularly in Africa. The associated disease burden is substantial, with high mortality among people with AIDS; host genetic variation, including HLA alleles, is being investigated as a potential determinant of susceptibility to cryptococcal disease in people with HIV. [309]
Tuberculous meningitis is an important alternative diagnosis to acute bacterial meningitis. Distinguishing the two may be especially difficult after empirical antibiotic exposure. A prospective cohort included 125 patients with bacterial meningitis and 56 with tuberculous meningitis, regardless of pre-admission antibiotic treatment, and evaluated cerebrospinal-fluid procalcitonin and neutrophil percentage as discriminatory markers. [294]
Zoonotic and environmental triggers
Leptospirosis can cause central nervous system disease, including leptospiral-associated meningitis, although CNS involvement is uncommon and under-recognized. Evidence from northeastern Brazil combined three institutional cases with a meta-summary of 176 published cases, indicating that leptospiral meningitis should be considered in compatible patients with exposure risk in tropical or endemic settings. [295]C
Host and contextual factors
Immunosuppression is an important context for unusual or opportunistic meningitis. In a real-world evaluation of a multiplex meningitis–encephalitis panel, positive results in cerebrospinal-fluid samples with fewer than 10 leukocytes/µL occurred exclusively in immunocompromised individuals and children, emphasizing that a low inflammatory-cell count does not exclude infection in these groups. [299] HIV is specifically associated with cryptococcal meningitis, while systemic lupus erythematosus and chronic renal failure were present in a reported case of E. coli meningitis after cupping and acupuncture. [309][305]C
Clinical presentation alone may not reliably identify the cause. Serum procalcitonin has been evaluated in adults with intracranial infection, and cerebrospinal-fluid NGAL, heparin-binding protein, procalcitonin, and conventional markers have been studied to distinguish acute bacterial meningitis from other CNS infections and inflammatory diseases; these tests support etiologic classification but do not replace microbiologic evaluation. [300][298]
Practical etiologic considerations
Etiologic assessment should incorporate age—especially ≤90 days in febrile infants—immune status, vaccination, recent neurosurgery, geographic residence or travel, zoonotic exposure, congenital findings, and prior antimicrobial treatment. [293][282][295]C[296][297]C[307]C[309] Rapid molecular panels can assist early pathogen identification, but their restricted target range means that a negative result does not exclude bacterial meningitis when clinical and cerebrospinal-fluid findings remain strongly suggestive. [299][302]C[306]C
| Etiologic category | Associated context or trigger | Evidence |
|---|---|---|
| Bacterial | Infancy, childhood, adulthood; regional pathogen and resistance patterns | [282][288] |
| Pneumococcal | Incomplete or altered vaccine-serotype protection; emergence of non-vaccine serotypes | [297]C |
| Postoperative/post-neurosurgical bacterial | Posterior fossa tumor surgery or other neurosurgical treatment | [301][304] |
| Viral congenital | Maternal/congenital LCMV infection with placental and fetal neurologic abnormalities | [307]C |
| Fungal | Southwestern US or Texas exposure for Coccidioides; HIV-associated immunosuppression for Cryptococcus | [296][308][309] |
| Tuberculous | Alternative CNS infection, including after empirical antibiotic exposure | [294] |
| Zoonotic | Leptospira exposure in tropical or endemic settings | [295]C |
| Unusual healthcare or procedural exposure | Cupping and acupuncture preceding reported E. coli meningitis | [305]C |
Pathophysiology
- ▸Meningitis reflects diverse infectious or immune-mediated inflammatory mechanisms, and extension into brain tissue produces meningoencephalitis. [361][365][369]
- ▸Bacterial, tuberculous, fungal, amoebic, zoonotic, and atypical infections may produce overlapping CSF and clinical phenotypes. [288][332][366][369][371][372]
- ▸TBM is often paucibacillary and may progress from meningeal inflammation to parenchymal disease, hydrocephalus, and permanent neurological injury. [369][370]
- ▸Chronic fungal meningitis can disrupt CSF circulation and ventricular mechanics, while cryptococcal disease may also cause vascular injury and ischemic stroke. [313][372]
- ▸Aseptic meningitis may accompany histiocytic necrotizing lymphadenitis or NPSLE, making exclusion of CNS infection essential. [310][365]
- ▸Rapid multiplex PCR and metagenomic sequencing can shorten or broaden etiologic diagnosis, but results require clinical and CSF correlation. [361][362][363][367]
Overview
Meningitis is an inflammatory syndrome involving the meninges and cerebrospinal fluid (CSF), which may extend into the brain parenchyma and produce meningoencephalitis. The underlying process is heterogeneous: infection may be bacterial, viral, mycobacterial, fungal, parasitic, or zoonotic, while aseptic inflammation may arise from immune-mediated disease, malignancy, drugs, or postoperative tissue injury. The available evidence emphasizes that these mechanisms can produce overlapping clinical and CSF phenotypes, making the biological cause difficult to distinguish early. [361][362][363][365]C[366]C[369]C
Infectious mechanisms
Bacterial meningitis results from invasion of the CSF and an acute inflammatory response that is commonly characterized by CSF pleocytosis and neutrophil predominance. In pediatric bacterial meningitis, the pathogen distribution is regionally variable and includes both community-acquired and post-neurosurgical organisms; antimicrobial resistance further modifies the clinical course and treatment response. [288] In postoperative meningitis after pediatric posterior-fossa tumor surgery, surgical intervention and CSF leakage or contamination provide a context in which culture-positive and culture-negative inflammatory syndromes may occur, and early CSF cytology can assist recognition. [301] Post-neurosurgical meningitis is sufficiently heterogeneous that culture results may require 3–5 days, creating a period in which inflammation is present before the responsible organism is confirmed. [368]
Tuberculous meningitis (TBM) is caused by meningeal infection with Mycobacterium tuberculosis. Its CSF is often paucibacillary, and limited specimen volume contributes to diagnostic attrition across molecular, culture, and susceptibility-testing workflows. [370] Progressive tuberculous meningeal inflammation can extend into the brain parenchyma, producing encephalitis, neurological complications, and irreversible sequelae, particularly when recognition is delayed in children. [369]C TBM may also be associated with hydrocephalus and severe neurological disability; contemporary treatment studies have focused on agents with adequate CNS penetration, including linezolid and contezolid. [364]C
Fungal meningitis can produce chronic meningeal inflammation, impaired CSF circulation, vascular complications, and hydrocephalus. In coccidioidal meningitis, altered ventricular compliance and CSF-diversion failure may lead to low-pressure hydrocephalus, illustrating that chronic meningeal disease can disrupt both CSF dynamics and ventricular mechanics. [313]C Cryptococcal meningitis may cause lymphocytic CSF pleocytosis, increased protein, reduced glucose, communicating hydrocephalus, and inflammatory or vascular injury sufficient to produce ischemic stroke, including in a person with HIV and a relatively preserved CD4 count. [372]C
Primary amoebic meningoencephalitis (PAM), caused by Naegleria fowleri, is a rapidly destructive CNS infection that clinically mimics bacterial meningitis. The resulting overlap can delay organism-specific recognition and treatment, particularly in neonates and infants, in whom reported outcomes are frequently poor. [332]C Other atypical pathogens can also invade the meninges: confirmed examples include Chlamydia psittaci diagnosed by CSF quantitative PCR and serology, and possible Mycoplasma pneumoniae-associated meningoencephalitis identified through serological patterns such as seroconversion, IgM positivity, or a single high titre. [371]C[366]C These cases support consideration of zoonotic and post-infectious or immune-associated mechanisms when routine bacterial testing is unrevealing. [371]C[366]C
Immune-mediated and aseptic inflammation
Aseptic meningitis and meningoencephalitis may occur without an identified bacterial pathogen. In children with histiocytic necrotizing lymphadenitis, CNS involvement was uncommon but included both aseptic meningitis and meningoencephalitis, indicating that systemic histiocytic inflammation can extend to the meninges or brain. [365]C Neuropsychiatric systemic lupus erythematosus (NPSLE) is another important noninfectious mechanism; because neuropsychiatric symptoms may also reflect CNS infection, diagnostic attribution requires separating immune-mediated CNS injury from infection. CSF anti-suprabasin antibody has been investigated as a potential biomarker for this distinction. [310]
Consequences of meningeal inflammation
Regardless of cause, inflammation may alter CSF composition, increase protein, reduce glucose, and produce leukocyte recruitment, although the pattern varies among bacterial, tuberculous, fungal, immune-mediated, and atypical infections. [294][365]C[372]C In bacterial disease, CSF procalcitonin and neutrophil percentage have been evaluated to distinguish bacterial from tuberculous inflammation, including after antibiotic exposure. [294] Serum procalcitonin is also being assessed as a marker of intracranial infection in adults, but its diagnostic role is adjunctive rather than a direct measure of meningeal pathophysiology. [300]
Inflammation can impair CSF circulation and cause hydrocephalus, as demonstrated in coccidioidal and cryptococcal meningitis. [313]C[372]C It may also extend into neural tissue, producing meningoencephalitis, or contribute to vascular injury and ischemic stroke. [369]C[372]C The biological urgency therefore reflects not only the presence of microorganisms but also the host inflammatory response, parenchymal extension, vascular involvement, and disruption of CSF homeostasis. [313]C[369]C[372]C
Diagnostic implications of the mechanism
Because pathogen burden may be low, antibiotics may reduce culture sensitivity, and clinical phenotypes overlap, molecular testing can identify infectious causes more rapidly than conventional methods. A multiplex meningitis/encephalitis panel can detect 14 pathogens in approximately 1 hour, while broader multiplex PCR assays have targeted 85 meningitis-associated pathogens; CSF metagenomic sequencing provides another approach when routine testing is negative or atypical infection is suspected. [361][362][367] Diagnostic stewardship workflows and parallel laboratory testing may increase pathogen detection in resource-limited settings. [363] These tools do not replace clinical interpretation: positive molecular findings must be reconciled with CSF inflammation, imaging, host factors, and competing immune-mediated or postoperative explanations. [310][363][367]
| Mechanism | Illustrative pathophysiological consequences |
|---|---|
| Bacterial or post-neurosurgical infection | Acute CSF inflammation, neutrophil-predominant responses, culture-positive or culture-negative postoperative syndromes, and antimicrobial-resistance-related treatment complexity. [288][301][368] |
| Tuberculous infection | Paucibacillary CSF disease, progressive meningeal inflammation, parenchymal extension, hydrocephalus, and neurological sequelae. [369]C[370] |
| Fungal infection | Chronic meningeal inflammation, impaired CSF circulation, hydrocephalus, altered ventricular compliance, and possible vascular injury. [313]C[372]C |
| Amoebic or atypical infection | Rapidly destructive PAM or zoonotic/post-infectious meningoencephalitis that may mimic common bacterial disease. [332]C[366]C[371]C |
| Immune-mediated or aseptic inflammation | Meningeal or parenchymal inflammation without confirmed bacterial infection, including HNL-associated disease and NPSLE. [310][365]C |
History and Physical Examination
- ▸In infants, fever or hypothermia may be the principal manifestation of invasive bacterial infection; assess temperature instability and overall appearance carefully. [60][116]
- ▸Document consciousness, seizures, status epilepticus, rash, focal neurological findings, and cranial-nerve or hearing abnormalities. [81][319][373]
- ▸Ask about CSF leakage, skull-base disease or surgery, otogenic infection, and cochlear implantation because these are relevant meningitis risk contexts. [51][107]
- ▸Assess HIV status, antiretroviral therapy, viral suppression, and prior neurological disease when evaluating new-onset seizures. [337]
- ▸Arrange structured follow-up for neurological sequelae and formal audiological testing because deficits may be underrecognized after apparent clinical recovery. [33][34]
Clinical context and presenting features
The initial history should establish age, fever or temperature instability, symptom onset, immune status, relevant exposures, and risk factors for invasive bacterial infection (IBI). In young infants, fever may be the only clinical manifestation of bacteremia or bacterial meningitis; routine assessment should therefore not rely on the presence of focal neurological findings. [60] Hypothermia is also clinically relevant: among infants aged 0–60 days presenting with a temperature of ≤36.0°C, IBI was identified in a retrospective cohort, although the reported prevalence was low. [116]D Febrile infants aged ≤28 days are commonly evaluated with lumbar puncture because of the risk of bacterial meningitis, and prediction-rule research has specifically assessed whether a subgroup can be classified as low risk. [60]
For febrile infants aged 60–90 days, the history and examination should document appearance, feeding, activity, perfusion, respiratory status, and the duration and measured degree of fever, because this age group has variable guideline recommendations and a measurable prevalence of bacteremia and bacterial meningitis. [282] A positive urinalysis does not exclude IBI; a UK and Ireland prospective cohort specifically evaluated the prevalence of bacteremia or bacterial meningitis among febrile infants aged ≤90 days with positive urinalysis results. [44] Machine-learning studies in infants aged ≤90 days have likewise focused on identifying IBI from clinical and laboratory information, but systematic-review evidence indicates that the role and diagnostic performance of these models remain under evaluation rather than replacing clinical assessment. [293]
Neurological and systemic examination
The examination should document level of consciousness, mental status, seizures, focal neurological abnormalities, and signs of systemic illness. Altered level of consciousness is a clinically important feature in adults with polymerase-chain-reaction-confirmed varicella-zoster-virus meningitis and was examined in relation to viral load, pathophysiology, and outcome. [81]D The presence of a vesicular or dermatomal rash should be recorded, but its absence should not be used to exclude VZV meningitis because the cited cohort specifically evaluated patients with and without rash. [81]D
Seizure history should include the first seizure, recurrence, duration, status epilepticus, focality, and relationship to the acute illness. Acute symptomatic seizures are recognized as a frequent complication of meningitis and may be life-threatening; they are also associated with subsequent epilepsy risk. [319] In a comparative study of status epilepticus associated with tuberculous meningitis and scrub typhus, 28 of 587 meningitis patients had status epilepticus, comprising 17 patients with tuberculous meningitis and 11 with scrub typhus. [373] These data support documenting the presumed meningitis etiology, seizure semiology, and recovery of consciousness rather than recording “seizure” as a nonspecific symptom. [373]
In people living with HIV, the history should include antiretroviral therapy, viral suppression, prior opportunistic or central nervous system infections, and seizure recurrence. A prospective cohort of adults with HIV and new-onset seizures evaluated two-year seizure recurrence in the era of broadly available antiretroviral therapy; only 25 of 64 (39%) participants receiving antiretroviral therapy were virally suppressed, and 12 of 89 (13%) presented in status epilepticus. [337]
Predisposing conditions and route of infection
Ask specifically about cerebrospinal-fluid leakage, prior skull-base trauma or surgery, otitis or other otogenic disease, and cochlear implantation. CSF leakage is a recognized risk factor for bacterial meningitis, and a national pediatric cohort identified meningitis in children with meningeal breach or cochlear implants. [51]D In that cohort, 251 of 5,879 (4.3%) bacterial meningitis cases in children older than 3 months occurred in the CSF-leakage population. [51]D Spontaneous lateral skull-base CSF-leak studies have compared meningitis rates before and after repair, emphasizing the relevance of identifying an active or repaired leak in the history. [107]
The ear, mastoid region, cranial nerves, and hearing should be examined and documented at presentation and during recovery. Histopathological evidence shows cochlear injury in both otogenic and meningogenic meningitis, with greater cochlear damage reported in otogenic disease. [374] Formal audiological testing is important after infectious meningitis because sensorineural hearing loss may be missed during routine bedside examination; a global systematic review evaluated the optimal timing of formal testing and follow-up. [34] A history of hearing difficulty, tinnitus, vertigo, imbalance, delayed language development, or school and occupational difficulty should therefore prompt formal audiological assessment. [34]
Follow-up history and examination
The review should not end when fever and cerebrospinal-fluid abnormalities improve. Neurological sequelae after acute meningitis may affect more than 30% of survivors worldwide, although they are frequently underreported or undetected because of inadequate follow-up, limited healthcare access, and diagnostic challenges. [33] Follow-up assessment should therefore reassess cognition, behavior, memory, motor function, balance, cranial-nerve function, seizures, sleep, mood, and hearing, with timing individualized to the patient’s age, severity, and deficits. [33] Formal audiological testing should be arranged when hearing loss is suspected or when clinically appropriate after meningitis, because early detection of meningitis-associated sensorineural hearing loss may reduce permanent deafness and related cognitive, social, and mental-health consequences. [34]
Practical documentation
Record the patient’s age and temperature pattern; appearance and perfusion; mental status and consciousness; seizures and status epilepticus; rash; focal neurological findings; ear and cranial-nerve findings; hearing and vestibular symptoms; immune status; HIV and antiretroviral history when applicable; CSF-leak, skull-base, otologic, surgical, or cochlear-implant history; and functional deficits identified during follow-up. These elements correspond to the clinical variables and sequelae emphasized in the cited infant, adult, pediatric, seizure, CSF-leak, and hearing studies. [33][34][51]D[60][81]D[107][116]D[293][319][337][373]
Diagnosis and Workup
- ▸Define suspected CNS infection using the clinical syndrome and CSF pleocytosis; one prospective adult study used **≥5 CSF cells/μL**.[361]
- ▸Obtain CSF culture and molecular testing in parallel when possible because antibiotics reduce conventional diagnostic yield and culture may take **3–5 days** post-neurosurgery.[361][368]
- ▸Use multiplex PCR, broad multiplex assays, and mNGS as complementary tools; MeltArray CNS targets **85 pathogens**, while FilmArray ME detects **14 pathogens in approximately 1 hour**.[361][362]
- ▸Interpret CSF and serum procalcitonin as adjunctive biomarkers rather than definitive etiologic tests.[294][300]
- ▸Consider TBM, cryptococcosis, PAM, Listeria, postoperative infection, autoimmune disease, histiocytic necrotizing lymphadenitis, and Mycoplasma-associated disease according to host factors and clinical context.[315][326][332][365][366]
- ▸Do not use PPD, serology, isolated biomarkers, or a negative molecular assay as a standalone rule-in or rule-out test.[310][362][366][375]
Immediate assessment and case definition
Meningitis and meningoencephalitis require urgent evaluation because delayed or inappropriate treatment is associated with substantial morbidity and mortality. Diagnostic assessment should therefore proceed in parallel with clinical stabilization, cerebrospinal-fluid (CSF) sampling, microbiological testing, and empiric management when bacterial, tuberculous, fungal, or amoebic disease is plausible.[361][363] In adults enrolled in a prospective Japanese study, suspected CNS infection was defined by a compatible syndrome with CSF pleocytosis of ≥5 cells/μL; the cohort included meningitis, meningoencephalitis, and myelitis.[361]
The initial assessment should document age, immune status, pregnancy, recent antimicrobial exposure, neurosurgery or head trauma, healthcare exposure, tuberculosis exposure, travel or freshwater exposure, systemic infection, malignancy, and autoimmune disease, because these contexts alter the differential diagnosis and test selection.[332]C[288][301][326][310] Altered consciousness, focal motor deficits, or abnormal neuroimaging are clinically important severity features; in a cryptococcal meningitis cohort, impaired consciousness and motor deficits were independently associated with unfavorable outcome.[326]
CSF and routine laboratory evaluation
CSF should be evaluated using cell count and differential, protein, glucose, Gram stain, bacterial culture, and targeted molecular testing, with blood cultures and relevant systemic investigations obtained when bacterial disease is suspected.[288][315]C[363] Interpretation must account for prior antibiotics: conventional CSF diagnostics may have reduced sensitivity after antimicrobial exposure, while culture-based results can take 3–5 days in post-neurosurgical meningitis.[361][368] In pediatric Listeria meningitis, CSF culture was positive in 10/11 (90.9%) cases, whereas CSF PCR confirmed infection in 9/9 tested patients, illustrating the complementary value of culture and PCR.[315]C
Routine CSF findings may help prioritize testing but do not reliably establish etiology. In antibiotic-pretreated patients, CSF procalcitonin and the CSF neutrophil percentage were specifically evaluated to distinguish bacterial meningitis from tuberculous meningitis; these markers should be interpreted as adjuncts rather than replacements for microbiological confirmation.[294] Serum procalcitonin has also been evaluated in a systematic review and meta-analysis of 10 studies assessing its diagnostic accuracy for adult intracranial infection, but serum procalcitonin alone should not be treated as definitive proof of meningitis.[300]
Molecular and metagenomic testing
A multiplex molecular assay can shorten time to etiologic diagnosis. The FilmArray Meningitis/Encephalitis Panel detects 14 pathogens in approximately 1 hour and, in a prospective adult before-and-after study, was assessed for its effect on diagnosis and empirical acyclovir use.[361] Its results should be reconciled with CSF cell counts, chemistry, culture, Gram stain, host factors, and the possibility of pathogens outside the panel.[361]
Broader multiplex testing may be useful when the clinical differential is wide or tuberculosis is suspected. MeltArray CNS targets 85 meningitis-associated pathogens; it was compared with metagenomic next-generation sequencing (mNGS) in 79 CSF specimens and prospectively assessed in 255 patients with suspected meningitis.[362] CSF mNGS was evaluated in 46 patients with suspected encephalitis, meningitis, or meningoencephalitis against a composite clinical reference standard, with interpretation based on the degree of etiologic certainty and read-count stratification.[367] mNGS findings therefore require clinical correlation because detection may represent contamination, colonization, or an incidental signal rather than causation.[367]
Diagnostic stewardship can improve yield where laboratory resources are limited. In a prospective study of 103 adults in Lima, Peru, a diagnostic-stewardship workflow processed CSF in parallel through the hospital laboratory and an independent reference laboratory, allowing within-patient comparison with standard care.[363] The workflow supports parallel rather than sequential testing when delay or limited local capability threatens diagnostic confirmation.[363]
Targeted evaluation for important etiologies
Tuberculous meningitis should be considered when the course is subacute, systemic or epidemiologic risk is present, or routine bacterial testing is unrevealing. Pediatric TBM is especially difficult to recognize early, and delayed identification may permit progression to parenchymal involvement and irreversible neurologic sequelae.[369]C Multiplex PCR has been specifically investigated to distinguish TBM from other meningitides in high-burden settings, where overlapping clinical features and delayed conventional assays complicate diagnosis.[362] PPD reactivity reflects cellular immune response but should not be used alone to confirm or exclude TBM; its relationship with mortality varies across age groups.[375]
Cryptococcal meningitis warrants dedicated fungal testing and neuroimaging, particularly in immunocompromised or HIV-negative patients. In a cohort of 181 patients, neuroimaging and neurologic examination findings—including impaired consciousness and motor deficits—were associated with outcome, supporting early assessment for complications and need for specialist intervention.[326]
Primary amoebic meningoencephalitis caused by Naegleria fowleri can mimic bacterial meningitis, especially in neonates and infants, creating a risk of misdiagnosis and delayed treatment.[332]C A compatible fulminant presentation with freshwater exposure or an atypical bacterial workup should prompt urgent specialist consultation and targeted amoebic testing.[332]C
Other mimics require directed testing. In children with fever, lymphadenopathy, and aseptic meningitis or meningoencephalitis, histiocytic necrotizing lymphadenitis should be considered; a 26-case pediatric series included 23 cases of aseptic meningitis and 3 of meningoencephalitis and characterized associated laboratory and MRI findings.[365]C Mycoplasma-associated meningoencephalitis has been categorized using seroconversion, IgM positivity, or a single high antibody titre of ≥1:320, but serology-based attribution remains probabilistic and should be interpreted with CSF and clinical findings.[366]C In patients with systemic lupus erythematosus and neuropsychiatric symptoms, CSF anti-suprabasin antibody has been prospectively evaluated to distinguish neuropsychiatric SLE from CNS infection and non-NPSLE conditions, but it is an adjunct to multidisciplinary diagnostic adjudication.[310]
Post-neurosurgical meningitis requires separate interpretation because postoperative inflammation can resemble infection. In pediatric posterior-fossa tumor surgery, early CSF cytology, CSF characteristics, microbiology, and perioperative risk factors were evaluated in a cohort of 116 cases.[301] Culture results should be interpreted alongside cytology and the operative context rather than in isolation.[301][368]
Interpretation and limitations
A negative culture or multiplex result does not exclude meningitis when antibiotics preceded sampling, when the organism is not included in the assay, or when an inflammatory mimic is present.[361][362][363] Conversely, molecular detection should be weighed against specimen quality, organism burden, contamination risk, and clinical compatibility.[367] Steroid studies in TBM demonstrate that adjunctive therapy is an outcome question rather than a diagnostic test; pooled evidence found reduced adult mortality but no statistically significant mortality benefit in children, underscoring the need to establish the likely etiology before interpreting treatment effects.[325] Contezolid and linezolid studies in TBM likewise concern treatment outcomes and safety, not diagnostic confirmation.[364]C
| Clinical context | Priority investigations | Key limitation |
|---|---|---|
| Acute meningitis or meningoencephalitis | CSF cell count/differential, chemistry, Gram stain, culture, blood cultures, and targeted molecular testing | Prior antibiotics may reduce conventional test sensitivity.[361][363] |
| Suspected TBM | TB-directed CSF testing, multiplex PCR, imaging, and epidemiologic assessment | Clinical overlap and delayed confirmation are common.[362][369]C |
| Suspected cryptococcosis | Dedicated fungal testing plus neuroimaging and neurologic assessment | Outcome risk is increased with impaired consciousness or motor deficits.[326] |
| Neonate or infant with fulminant bacterial-like meningitis | Urgent consideration of Naegleria fowleri and targeted testing when exposure or atypical features support it | PAM can closely mimic bacterial meningitis.[332]C |
| Post-neurosurgical or postoperative meningitis | Culture, molecular testing, CSF cytology, CSF characteristics, and operative-risk review | Postoperative inflammation can confound interpretation.[301][368] |
| SLE with new neuropsychiatric symptoms | Infection evaluation plus autoimmune assessment; CSF anti-SBSN may be adjunctive | Biomarker attribution requires clinical adjudication.[310] |
Differential Diagnosis of Meningitis
- ▸Antibiotic administration prior to lumbar puncture occurs in nearly 45% of cases and significantly impairs the sensitivity of CSF cultures, necessitating the use of molecular methods like multiplex PCR or mNGS.
- ▸GFAP astrocytopathy is a critical autoimmune mimic of infectious meningitis, often distinguishable by linear perivascular radial enhancement on MRI and a positive response to corticosteroids.
The differential diagnosis of meningitis is broad, encompassing infectious, autoimmune, and neoplastic etiologies that often present with overlapping clinical features such as fever, headache, and meningismus. Distinguishing between these entities is critical, as strategies vary significantly—ranging from urgent antimicrobial therapy for bacterial pathogens to immunosuppression for autoimmune mimics like (GFAP) astrocytopathy [131][143]C. ### Diagnostic Criteria Formal diagnosis of meningitis requires a combination of clinical suspicion and laboratory confirmation.
Management of Meningitis
- ▸Empiric antibiotics (e.g., Ceftriaxone 2 g + Vancomycin 15-20 mg/kg) must be administered within 60 minutes of presentation to reduce mortality.
- ▸Dexamethasone (0.15 mg/kg) should be given before or with the first antibiotic dose to mitigate the inflammatory response to bacteriolysis.
The of is a medical emergency requiring rapid stabilization, immediate administration of empiric antimicrobials, and targeted adjunctive therapies to mitigate neuroinflammation. Delay in treatment is a primary driver of poor outcomes, particularly in bacterial and tuberculous forms where the host immune response often exacerbates brain injury [73]D[158]. ### Step 1: Initial Assessment and Severity Classification Upon presentation, clinicians must immediately assess for signs of increased intracranial pressure (ICP) and systemic instability.
Supportive Care and Complication Management
- ▸Begin empiric antimicrobial treatment promptly when acute bacterial meningitis is suspected; the optimal early-versus-delayed threshold remains uncertain in the available evidence [331].
- ▸Use local pediatric pathogen and antimicrobial-resistance data to guide empiric therapy, particularly after neurosurgery [288].
- ▸Consider uncommon etiologies such as Naegleria fowleri, Listeria, Leptospira, and West Nile virus when clinical or epidemiological features are atypical [332,315,98,335].
- ▸Individualize ASM duration after meningitis-associated acute symptomatic seizures; the key evidence comparison is cessation within versus beyond **3 months** [319].
- ▸LD/EVD may be considered for severe meningitis with raised ICP or CSF-flow obstruction, but indications and timing are not standardized [166].
- ▸Arrange structured post-discharge surveillance, including formal hearing assessment and neurological, cognitive, developmental, and seizure follow-up [33,34,333].
Immediate supportive priorities
Acute bacterial meningitis is a medical emergency: empiric antimicrobial treatment should be initiated promptly when bacterial meningitis is suspected, because delayed therapy may increase mortality and neurological sequelae [331]. The available 2026 systematic review identified three prospective cohort studies comparing earlier with delayed empiric treatment, but the supplied evidence does not establish a definitive timing threshold or a universally superior strategy [331]. Empiric regimens should therefore be selected according to age, immune status, exposure history, local epidemiology, and antimicrobial-resistance data, with subsequent narrowing when microbiological results become available [288]. Pediatric pathogen distribution and resistance patterns are region-specific and dynamic; a 7-year study from Southwest China included 258 culture-positive children and specifically emphasized the importance of local surveillance, particularly in post-neurosurgical meningitis [288].
The differential diagnosis should remain broad when the presentation or cerebrospinal-fluid findings are atypical. Naegleria fowleri primary amoebic meningoencephalitis can mimic bacterial meningitis, and delayed recognition in neonates and infants is associated with poor outcomes [332]C. Other regionally or epidemiologically relevant causes include neuroleptospirosis, which was investigated among patients presenting with meningitis, meningoencephalitis, or encephalitis in a multicentre Sri Lankan study [98]D, and neuroinvasive West Nile virus infection, which included meningitis and meningoencephalitis during an Istanbul outbreak [335]C. Listeria monocytogenes should remain a consideration beyond the neonatal period; a Turkish multicentre pediatric series described 11 previously unpublished, microbiologically confirmed cases in children aged 1 month to 18 years [315]C.
Seizures and antiseizure medicines
Acute symptomatic seizures are a potentially life-threatening complication of meningitis and may indicate increased risk of subsequent epilepsy [319]. The optimal duration of antiseizure medication (ASM) after meningitis-associated acute symptomatic seizures remains uncertain; a 2026 systematic review and meta-analysis compared cessation within 3 months of treatment initiation with cessation after more than 3 months [319]. Decisions about continuation or withdrawal should therefore be individualized according to seizure recurrence, electroclinical findings, structural injury, neurological examination, and specialist follow-up; the supplied abstract does not provide sufficient outcome estimates to mandate one duration for all patients [319]. Evidence from adults with HIV and new-onset seizures is not specific to meningitis, although it demonstrates that recurrence and mortality remain clinically important outcomes requiring follow-up in immunocompromised populations [337]. Veterinary epilepsy data should not be extrapolated to human meningitis management [327].
Raised intracranial pressure, hydrocephalus, and CSF diversion
Raised intracranial pressure (ICP) is associated with substantial morbidity and mortality in meningitis [166]. Lumbar drainage and external ventricular drainage (LD/EVD) have been used as adjuncts to antimicrobial therapy in severe disease, but there is no established standard for incorporating CSF diversion into routine meningitis care [166]. A systematic review identified 41 studies of LD and/or EVD and emphasized consideration of divertive treatment even when hydrocephalus is not demonstrated; this evidence should be interpreted by multidisciplinary teams because the optimal device, indications, and timing remain unsettled [166].
Post-meningitic hydrocephalus may require temporary CSF diversion in children. In a pediatric cohort managed with an Ommaya reservoir, delayed CSF sterilization was defined as requiring more than 14 days to obtain two sterile cultures collected at least 48 hours apart; a multivariable prediction model was developed to estimate this risk [336]. Persistent infection, impaired consciousness, focal deficits, or radiological hydrocephalus warrant urgent neurosurgical and infectious-disease assessment [326][336]. In cryptococcal meningitis, choroid plexitis may cause ependymitis, synechiae, trapped ventricles, and obstructive hydrocephalus, while gelatinous pseudocysts may contribute to false-negative smear or culture results [334]. A retrospective cohort of 181 cryptococcal meningitis patients evaluated neuroimaging predictors and surgical intervention, with unfavorable 12-month outcomes reported more often in HIV-negative than HIV-positive patients (19.1% vs 5.0%) [326].
Fungal, granulomatous, and inflammatory complications
Cryptococcal meningitis may occur in immunocompetent as well as immunocompromised individuals and can present with seizures, altered mentation, and obstructive CSF-flow abnormalities [334]. Pediatric central nervous system coccidioidomycosis is severe and generally requires lifelong antifungal therapy; fluconazole is recommended as initial treatment in children, although fluconazole failure has prompted use of intravenous liposomal amphotericin B in case-series practice [163]C. Tuberculous meningitis in childhood carries a high risk of death or severe neurological sequelae, and age-disaggregated clinical predictors have been studied in children younger than 15 years [292]. Neuropsychiatric systemic lupus erythematosus may produce inflammatory or leukodystrophy-like neurological syndromes, but evidence concerning anifrolumab is based on rationale, case reports, and systematic literature review rather than randomized trials in neuropsychiatric disease [129][85]. These inflammatory disorders should not be presumed to represent infectious meningitis without appropriate diagnostic evaluation [129][85].
Discharge planning and surveillance for sequelae
Follow-up should actively assess neurological, cognitive, behavioral, motor, and sensory outcomes because post-meningitic sequelae may be underdetected when review is delayed or access to healthcare is limited [33]. Formal audiological testing is important after acute infectious meningitis because sensorineural hearing loss may otherwise remain unrecognized; early detection can reduce the consequences of permanent deafness, including cognitive, social, and mental-health effects [34]. Childhood bacterial meningitis is associated with post-discharge complications, and a systematic review and meta-analysis evaluated these outcomes in patients aged 29 days to 18 years [333]. Discharge plans should therefore include scheduled clinical review, hearing assessment, seizure review, developmental and educational screening in children, rehabilitation referral where needed, and clear return precautions for worsening headache, altered consciousness, recurrent seizures, focal deficits, or fever [33][34][333].
| Complication or risk | Supportive-care action | Evidence |
|---|---|---|
| Acute symptomatic seizures | Treat acutely and reassess the need and duration of ASM individually; compare withdrawal decisions against the unresolved 3-month threshold | [319] |
| Raised ICP or hydrocephalus | Obtain urgent specialist assessment; consider LD/EVD when clinically indicated, recognizing the absence of a standardized approach | [166][336] |
| Hearing loss | Arrange formal audiological testing after infectious meningitis and provide early hearing rehabilitation when required | [34] |
| Long-term neurological sequelae | Schedule clinical, developmental, cognitive, behavioral, and functional review after discharge | [33][333] |
| Cryptococcal CSF-flow complications | Consider choroid plexitis, trapped ventricles, and obstructive hydrocephalus when imaging or microbiology is discordant | [334][326] |
Prognosis and Long-term Outcomes
- ▸Adjunctive linezolid in TBM showed a possible mortality benefit, but certainty was low: RR 0.55 with a 92% probability of preventing one death per 100 treated patients. [324]
- ▸Corticosteroids reduced mortality in adults with TBM but did not clearly improve neurological complications or functional recovery; pediatric mortality benefit was not statistically significant. [325]
- ▸Hyponatraemia was present in 92.6% of measured adults with TBM and correlated with greater disease severity and cerebrospinal-fluid inflammation. [311]
- ▸Stroke complicated 13% of childhood bacterial meningitis cases in one tertiary-center cohort and represents an important risk for neurological morbidity. [289]
- ▸At 12 months after cryptococcal meningitis, unfavorable outcome was more frequent in HIV-negative than HIV-positive patients, and impaired consciousness or motor deficits predicted worse outcome. [326]
- ▸Naegleria fowleri primary amoebic meningoencephalitis is often fatal in neonates and infants, particularly when diagnosis or treatment is delayed. [332]
Overview
Prognosis in meningitis is heterogeneous and depends on the causative organism, age, host factors, neurological severity at presentation, complications, and the speed and appropriateness of treatment. Delayed or inappropriate therapy is associated with worse outcomes in central nervous system infection, making rapid diagnosis and early targeted treatment important prognostic interventions. [361] Diagnostic-stewardship workflows and rapid molecular testing may improve pathogen detection and reduce unnecessary empirical treatment, although the cited studies do not establish their independent effect on long-term disability. [361][363]
Tuberculous meningitis
Tuberculous meningitis (TBM) remains associated with substantial risks of death and neurological disability. In a Bayesian meta-analysis of three randomized trials, adjunctive linezolid had a 92% probability of preventing one additional death per 100 treated patients, with a pooled risk ratio of 0.55 (95% credible interval, 0.23–1.31; I²=13%; 104 participants); however, the evidence was rated low certainty. [324] The reported estimate therefore suggests possible mortality benefit but remains compatible with little or no benefit.
Adjunctive corticosteroids appear to improve survival in adults with TBM: a meta-analysis of 14 trials involving 2,028 patients found reduced adult mortality (RR 0.83, 95% CI 0.72–0.95). The same analysis did not demonstrate a statistically significant reduction in mortality among children (RR 0.68, 95% CI 0.36–1.29), neurological complications overall (RR 1.03, 95% CI 0.74–1.44), or functional recovery; therefore, mortality benefit should not be assumed to mean prevention of long-term disability. [325]
Treatment complications can influence prognosis. In adults with TBM who developed drug-induced liver injury during treatment, a randomized comparison evaluated strategies involving continuation or selective withdrawal of antituberculosis drugs during the first 60 days after randomization; the available evidence summary does not report the comparative outcome results. [338] Hyponatraemia is common in TBM: 176 of 190 adults (92.6%) with a measured admission sodium level were hyponatraemic, and lower sodium was associated with more severe disease and greater cerebrospinal-fluid inflammation. [311] These findings identify hyponatraemia as a marker of illness severity, although they do not prove that correcting sodium independently improves long-term outcome.
Bacterial meningitis and neurological complications
Stroke is an important determinant of outcome in childhood bacterial meningitis. In a retrospective cohort of 540 children with laboratory-confirmed disease, stroke occurred in 72 patients (13%); the study specifically evaluated neurological outcomes in affected children, although the available evidence summary does not provide the final comparative outcome estimates. [289]
Invasive meningococcal disease may progress rapidly and is associated with high mortality and severe sequelae. In the cited Indian consensus, epidemic meningococcal disease had a reported case-fatality ratio of 12.8%, compared with 3.0% in endemic settings; the review also reported a 12.1% prevalence in epidemics and 0.76% in endemic settings, with the burden potentially underestimated because of weak surveillance. [287]
Group B streptococcal disease remains an important cause of morbidity and mortality in young infants. A Dutch prospective cohort identified 375 infants aged 0–89 days with culture-confirmed disease; 21% had definitive meningitis, while 55% had sepsis and 24% had probable meningitis. [359] The available summary does not provide the long-term neurodevelopmental outcome rates.
Viral, fungal, and amoebic disease
Primary amoebic meningoencephalitis caused by Naegleria fowleri is rare but often fatal, particularly in neonates and infants, and can be mistaken for bacterial meningitis; delayed recognition and treatment are associated with poor outcomes. [332]C
Cryptococcal meningitis outcomes vary by host status and neurological severity. In a retrospective cohort of 181 patients, the unfavorable 12-month outcome rate was higher in HIV-negative than HIV-positive patients (19.1% vs 5.0%). Impaired consciousness and motor deficits were independent adverse prognostic features, with reported odds ratios of 5.51 (95% CI 2.13–14.26) and 3.83, respectively. [326]
Long-term sequelae also occur after tick-borne encephalitis, an important meningoencephalitic illness. A Latvian cohort included 105 laboratory-confirmed adult cases hospitalized between 2018 and 2024 and reassessed patients at least 6 months after discharge for neurological, cognitive, and subjective sequelae; the available summary confirms persistent post-encephalitic outcomes were evaluated but does not provide their prevalence or predictor estimates. [340]
In children with enterovirus-associated meningoencephalitis during the EV71-vaccine era, EV71 accounted for 20 of 160 cases (12.3%), and the study reported no significant clinical or prognostic differences between EV71 and other enterovirus subtypes in the available summary. [328] Possible Mycoplasma pneumoniae-associated meningoencephalitis in adults was studied in 39 patients classified by serological pattern; the available summary describes clinical phenotypes but does not provide definitive long-term outcome estimates. [366]C
Prognostic assessment
Clinicians should assess consciousness, focal motor deficits, stroke, electrolyte disturbances, host immune status, and disease-specific complications early because these features are associated with outcome in the cited cohorts. [289][311][326] Prognostic estimates should be expressed with attention to evidence certainty: several available studies are retrospective or observational, and some summaries do not report complete long-term outcome data. [326][328][338][340]
Key implications
Survival does not necessarily imply neurological recovery; mortality and functional outcomes may respond differently to treatment, as illustrated by the corticosteroid meta-analysis in TBM. [325] Follow-up should therefore include neurological, cognitive, functional, and, when relevant, developmental assessment rather than mortality surveillance alone. [325][340]
| Condition or factor | Outcome-related evidence |
|---|---|
| TBM: adjunctive linezolid | RR 0.55; 92% probability of preventing one death per 100 treated; low-certainty evidence. [324] |
| TBM: corticosteroids | Adult mortality reduced, RR 0.83; no clear benefit for neurological complications or functional recovery. [325] |
| TBM: hyponatraemia | 92.6% of adults with measured admission sodium were hyponatraemic; lower sodium correlated with more severe disease. [311] |
| Pediatric bacterial meningitis | Stroke occurred in 13% of 540 children. [289] |
| Cryptococcal meningitis | Unfavorable 12-month outcome: 19.1% in HIV-negative versus 5.0% in HIV-positive patients. [326] |
| Meningococcal disease in India | Case-fatality ratio 12.8% in epidemics versus 3.0% in endemic settings. [287] |
Landmark Trials and Key Evidence
- ▸Early empiric antimicrobial treatment is biologically compelling, but comparative evidence remains limited to three prospective cohort studies in the cited review.[331]
- ▸High-dose rifampin regimens of up to 35 mg/kg have pharmacokinetic rationale, but pooled randomized evidence did not reduce all-cause mortality.[59][31][188]
- ▸Adjunctive linezolid showed a favorable probability signal but low-certainty evidence and a confidence/credible interval crossing no effect.[324]
- ▸Dexamethasone benefit in tuberculous meningitis may vary by LTA4H genotype, with greatest prior benefit associated with the hyperinflammatory TT genotype.[84]
- ▸Single-dose liposomal amphotericin B plus fluconazole is a tested strategy for preventing cryptococcal meningitis in people with HIV-associated cryptococcal antigenemia.[193]
- ▸Meningococcal vaccination evidence now includes a pentavalent conjugate vaccine covering serogroup X in addition to A, C, W, and Y.[190]
Scope and interpretation
Recent evidence spans acute bacterial, tuberculous, cryptococcal, neonatal, pediatric, vaccine-prevention, and immune-mediated meningitis. The strongest evidence comes from systematic reviews and meta-analyses of randomized controlled trials, although several contemporary studies remain limited by small samples, heterogeneous populations, or incomplete outcome information in the available reports.[324][319][331][31]
Acute bacterial meningitis: timing, duration, and adjunctive corticosteroids
Prompt empiric antimicrobial treatment is biologically and clinically important in acute bacterial meningitis, but the comparative evidence for “early” versus “delayed” administration remains limited. A systematic review identified three prospective cohort studies; the review used GRADE assessment, but the supplied abstract does not provide pooled effect estimates.[331] Antibiotic duration in children has also been reassessed. A systematic review and meta-analysis compared courses of ≤7 days with longer treatment, defined as 10 days or twice the short-course duration, for meningitis caused predominantly by Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis, evaluating treatment failure, death, neurologic sequelae, hearing impairment, and other complications.[343]
The role of adjunctive corticosteroids in pediatric bacterial meningitis remains controversial. A meta-analysis of randomized trials evaluated hearing loss and neurologic sequelae as primary outcomes, with fever resolution, mortality, secondary fever, and reactive arthritis as secondary outcomes.[185] The available abstract establishes the scope of the evidence but does not provide the pooled numerical results; therefore, corticosteroid benefit should not be generalized across all pediatric etiologies or outcomes solely from this review.[185]
For infants aged 0–59 days, a systematic review of randomized trials compared alternative antibiotic regimens and assessed critical clinical outcomes, reflecting the uncertainty surrounding optimal treatment in this high-risk age group.[342]
Tuberculous meningitis: intensified antimicrobial and adjunctive strategies
The 2025 double-blind, placebo-controlled trial of high-dose oral rifampin enrolled adults with tuberculous meningitis, with and without HIV, in Indonesia, South Africa, and Uganda. Participants received standard isoniazid, rifampin 10 mg/kg, ethambutol, and pyrazinamide, plus either additional rifampin to a cumulative dose of 35 mg/kg or placebo.[59] A 2026 meta-analysis pooled seven randomized trials involving 1,296 patients and reported that high-dose rifampin did not reduce all-cause mortality; the supplied abstract does not include the complete mortality estimate or serious-adverse-event result.[31]
Pharmacokinetic analyses explain the rationale for dose intensification. In adults with HIV-associated tuberculous meningitis, experimental regimens used oral rifampin 35 mg/kg or intravenous rifampin 20 mg/kg, with linezolid, with or without aspirin, versus standard oral rifampin 10 mg/kg; rifampin concentrations were modeled in plasma and cerebrospinal fluid on study days 3 and 28.[188] A nested pharmacokinetic study evaluated dexamethasone exposure in a randomized comparison of high-dose rifampin plus linezolid, with or without aspirin, versus standard-dose rifampin; all participants received dexamethasone beginning at 0.4 mg/kg/day, divided every 12 hours, and rifampin-associated reduction in dexamethasone exposure was a principal concern.[345]
Adjunctive linezolid has emerging but low-certainty support. A Bayesian meta-analysis of three randomized trials found a 92% probability that linezolid prevents one death per 100 treated patients, with pooled RR 0.55 (95% credible interval 0.23–1.31), low heterogeneity (I²=13%), and 104 participants.[324] The uncertainty interval crosses no effect, so linezolid should be viewed as investigational or selectively adjunctive rather than established mortality-reducing standard therapy.[324]
A randomized prospective pharmacokinetic study in 10 patients compared linezolid-containing and contezolid-containing regimens, five patients per group. Contezolid cerebrospinal-fluid concentrations exceeded the M. tuberculosis MIC of 0.5 μg/mL at 2 hours, with a median of 1.0806 μg/mL, but declined by 6 hours to a median of 0.7920 μg/mL; the study primarily addressed CSF exposure and safety, not clinical efficacy.[83]
Adjunctive corticosteroid therapy remains genotype-sensitive. In a phase 3 placebo-controlled trial of HIV-negative Vietnamese adults, 613 LTA4H CC- or CT-genotype participants were randomized to 6–8 weeks of dexamethasone or placebo, with a prespecified hazard-ratio noninferiority margin of 0.75 for placebo.[84] The trial was designed around evidence that benefit is more apparent in the hyperinflammatory TT genotype, whereas benefit is uncertain in CC and CT genotypes.[84]
Management of treatment toxicity has also been tested prospectively. Adults developing antituberculous-treatment drug-induced liver injury were randomized to: continuing all drugs unless severe biochemical or clinical thresholds were reached; stopping pyrazinamide unless predefined deterioration occurred; or stopping rifampin, isoniazid, and pyrazinamide while continuing ethambutol and adding levofloxacin plus an aminoglycoside.[338] The parent ACT HIV and LAST ACT corticosteroid trials contributed 520 and 720 participants, respectively, and the primary outcome was time on treatment during the 60 days after liver-injury randomization.[338]
Cerebrovascular complications and cryptococcal meningitis
The ACT-TBM randomized trial enrolled 237 patients in a secondary analysis examining cerebral infarction patterns, associated factors, and predictors; the parent trial evaluated aspirin or clopidogrel added to standard antituberculous therapy for stroke or cerebral infarction outcomes.[156]
In HIV-associated cryptococcal meningitis, AMBITION-cm data were used to study EBV and CMV coinfections and mortality; the parent randomized trial’s primary endpoint was 10-week all-cause mortality, and participants were recruited across seven sites in five African countries.[38] Pooled ACTA and AMBITION-cm trial data also supported development and validation of individualized mortality-prediction tools for adults with HIV-associated cryptococcal meningitis in sub-Saharan Africa.[189]
Pre-emptive therapy is another major prevention strategy. In Ugandan adults with HIV and asymptomatic cryptococcal antigenemia, single-dose liposomal amphotericin B 10 mg/kg plus fluconazole was compared with fluconazole alone for 24-week meningitis-free survival; historically, 25–30% of asymptomatic antigen-positive people receiving fluconazole alone developed breakthrough meningitis or died.[193]
Prevention and special populations
A phase 3 noninferiority trial in Mali evaluated the pentavalent meningococcal conjugate vaccine NmCV-5, targeting serogroups A, C, W, Y, and X, against MenACWY-TT when co-administered with routine childhood vaccines at ages 9 and 15 months.[190] Finally, evidence relevant to inflammatory mimics includes a systematic review of 90 studies addressing treatment of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus, a heterogeneous group that can resemble infectious meningitis but requires disease-specific management.[344]
Evidence gaps
Important uncertainties persist regarding optimal empiric-treatment timing, abbreviated pediatric antibiotic courses, corticosteroid selection, high-dose rifampin, linezolid and contezolid efficacy, genotype-guided dexamethasone use, and management of antituberculous drug-induced liver injury.[331][343][185][31][324][83][84][338]
| Evidence area | Design/population | Principal reported finding or endpoint |
|---|---|---|
| Adjunctive linezolid in TBM | Bayesian meta-analysis; 3 RCTs; n=104 | RR for death 0.55; 92% probability of preventing one death per 100 treated; low certainty.[324] |
| High-dose rifampin in TBM | Meta-analysis; 7 RCTs; n=1,296 | No reduction in all-cause mortality reported in the supplied abstract.[31] |
| High-dose rifampin trial | Double-blind RCT; adults with and without HIV | Standard regimen plus rifampin 35 mg/kg cumulative versus placebo.[59] |
| Genotype-stratified dexamethasone | Phase 3 RCT; HIV-negative Vietnamese adults; n=613 CC/CT | Dexamethasone versus placebo; placebo noninferiority margin HR 0.75.[84] |
| Cryptococcal antigenemia prevention | Randomized trial; adults with HIV in Uganda | Liposomal amphotericin B 10 mg/kg once plus fluconazole versus fluconazole; 24-week meningitis-free survival.[193] |
| NmCV-5 vaccination | Phase 3 noninferiority RCT; Malian infants | Pentavalent A, C, W, Y, X vaccine versus MenACWY-TT.[190] |
Special Populations
- ▸Both twins developed culture-confirmed GBS or Escherichia coli sepsis or meningitis in 46% of reported twin sets, so an apparently well co-twin may still require evaluation. [376]
- ▸Infants aged ≤90 days, neonates born preterm or with very low birth weight, and children with nonspecific illness require particular vigilance for meningitis and invasive bacterial infection. [271][293][348][350]
- ▸GBS disease in young infants included definitive meningitis in 21% of cases in a Dutch cohort. [359]
- ▸Pediatric meningitis may cause acute stroke and long-term educational or developmental consequences. [289][333][377]
- ▸Cryptococcal meningitis remains an important opportunistic infection in HIV, including occasional cases with relatively preserved CD4 counts. [349][372]
Neonates and young infants
Neonates and infants younger than 90 days require a low threshold for evaluation because invasive bacterial infection may present with subtle or nonspecific findings, and meningitis can progress rapidly. [293][348]C In a systematic review of twins in which at least one infant had culture-confirmed group B Streptococcus (GBS) or Escherichia coli sepsis or meningitis, both siblings developed disease in 46% of 151 twin sets; concordance was 35% in cohort or surveillance reports and 69% in case reports or case series. [376] A healthy-appearing co-twin therefore remains at clinically important risk and requires individualized assessment rather than reassurance based solely on appearance. [376]
Early-onset neonatal bacterial meningitis is particularly associated with prematurity and perinatal complications. [350] In a 20-year retrospective cohort, preterm infants had higher frequencies of premature rupture of membranes, apnea, and need for respiratory support than full-term infants. [350] Among very preterm and/or very-low-birth-weight infants with early-onset sepsis, probable meningitis was defined by culture-negative CSF with meningitis-consistent abnormalities, including pleocytosis and neutrophil predominance; a multicenter study developed a nomogram to predict this outcome after lumbar puncture. [271]
GBS remains an important cause of meningitis in young infants. [359] In a Dutch prospective multicenter cohort of 375 infants with culture-confirmed GBS disease, 21% had definitive meningitis, while 55% had sepsis and 24% had probable meningitis. [359] Early-onset disease accounted for 57% of cases and late-onset disease for 43%. [359] In a separate Saudi Arabian emergency-department cohort, invasive bacterial infections in infants aged ≤90 days were defined as bacteremia and/or bacterial meningitis, highlighting the need to consider meningitis within the broader invasive bacterial infection syndrome in this age group. [348]C
Acute neurological complications in neonatal bacterial meningitis include subdural effusion or empyema, ventriculitis, hydrocephalus, brain abscess, and encephalomalacia. [351] In a retrospective cohort of 68 neonates, 20 developed at least one such complication; the affected group differed from neonates without complications in age at symptom onset and laboratory findings. [351] Primary amoebic meningoencephalitis caused by Naegleria fowleri can mimic bacterial meningitis in neonates and infants, creating a risk of diagnostic delay; the condition is rare but frequently fatal, and early recognition and treatment were emphasized in a systematic review. [332]C
Children and adolescents
The epidemiology of pediatric central nervous system infection is heterogeneous. [346] In a population-based Danish cohort of previously healthy children aged 0–17 years, the annual incidence of microbiologically verified viral CNS infection was 49 per 1,000,000, bacterial meningitis 24 per 1,000,000, and cerebral abscess or empyema 7 per 1,000,000. [346] Group A streptococcal meningitis remains uncommon but severe; a nationwide Dutch cohort identified 27 pediatric cases from 2015 through June 2024, including children younger than 5 years. [378]C
Neurological and long-term sequelae are important considerations after childhood meningitis. [289][333][377]C In a pediatric bacterial meningitis cohort, stroke occurred in 13% of 540 children and was confirmed by neuroimaging; the study evaluated presentation, investigation, treatment, and neurological outcomes. [289] A systematic review and meta-analysis of post-discharge complications included bacterial meningitis in patients aged 29 days to 18 years, excluding tuberculosis meningitis, and synthesized complications using GRADE methodology. [333] A nationwide Danish cohort examining children with bacterial or enteroviral meningitis followed participants through 2024 and assessed school grades, completion of primary and secondary education, and higher-education attainment. [377]C
Listeria meningitis beyond the neonatal period is rare in children. [315]C A Turkish multicenter case series included 11 microbiologically confirmed cases from children aged 1 month to 18 years; CSF culture was positive in 90.9% of cases, and CSF PCR confirmed the diagnosis in all tested patients. [315]C
People living with HIV and advanced immunosuppression
Cryptococcal meningitis is a major opportunistic CNS infection in people living with HIV and is particularly associated with advanced immunosuppression. [349][372]C A systematic review and meta-analysis from Ethiopia evaluated the prevalence of opportunistic fungal infections, including cryptococcal meningitis and candidiasis, among HIV-positive individuals. [349] Cryptococcal meningitis can occasionally occur despite a relatively preserved CD4 count and may present with ischemic stroke; a case report described cryptococcal meningitis with infarction and communicating hydrocephalus in a patient with a CD4 count of 302 cells/mm³. [372]C
Hospitalized adults with advanced HIV disease and cryptococcal meningitis represent a population in whom tuberculosis prevention is difficult to deliver. [155] The IMPROVE phase 3 open-label, non-inferiority randomized strategy trial recruited adults aged ≥18 years admitted to tertiary hospitals in Uganda who were receiving treatment for cryptococcal meningitis, had advanced HIV disease, and had been screened for active tuberculosis during hospitalization. [155] It evaluated inpatient initiation and other delivery strategies for 1 month of daily rifapentine plus isoniazid (1HP), with the objectives of assessing safety, feasibility, and tuberculosis preventive-therapy uptake. [155]
Neurological complications may also occur in adults with HIV who present with new-onset seizures. [337] In a prospective cohort from rural Uganda, adults with HIV and new-onset seizures were followed for two years to assess seizure recurrence, with death treated as a competing outcome; the cohort included patients both receiving and not receiving antiretroviral therapy, and only a minority of treated participants were virally suppressed. [337] HIV-related neurological complications remain associated with substantial mortality in hospital-based cohorts, including a retrospective study from Cameroon conducted during the Test and Treat era. [284]
Pregnancy and congenital infection
Lymphocytic choriomeningitis virus is a rodent-borne infection capable of causing severe congenital disease involving the nervous system. [75]D In a Philadelphia seroepidemiologic study of pregnant women and newborns, LCMV IgG seroprevalence was 2.4% among 700 women selected from higher-risk neighborhoods and 2.7% among 300 randomly selected pregnant women. [75]D Seroprevalence varied by hospital site, maternal race or ethnicity, and neighborhood deprivation level. [75]D These findings support consideration of congenital and perinatal infections when neonatal neurological abnormalities resemble meningitis or other CNS disease. [75]D
| Population | Evidence-based consideration |
|---|---|
| Neonates and infants ≤90 days | Presentations may be subtle; assess for invasive bacterial infection and meningitis, including in an apparently healthy co-twin. [293][348]C[376] |
| Preterm or very-low-birth-weight infants | Early-onset sepsis may coexist with culture-negative, CSF-defined probable meningitis. [271] |
| Children and adolescents | Consider stroke and longer-term educational or functional sequelae after bacterial meningitis. [289][333][377]C |
| People with advanced HIV disease | Cryptococcal meningitis and other opportunistic fungal infections are important concerns; tuberculosis preventive therapy may be initiated during hospitalization in selected patients. [155][349] |
| Pregnant women and newborns | Congenital LCMV is an uncommon but potentially severe neurologic infection requiring consideration in appropriate epidemiologic or clinical contexts. [75]D |
Prevention and Screening
- ▸NmCV-5 targets meningococcal serogroups **A, C, W, Y, and X** and has been evaluated with routine childhood vaccines at **9 and 15 months** in Mali. [190]
- ▸MenAfriVac substantially reduced serogroup A epidemics in the African meningitis belt, but surveillance remains necessary for serogroups C, W, X, and other pathogens. [186][356][357]
- ▸Pneumococcal vaccination and antibiotic prophylaxis are particularly important in children with sickle cell disease; CSF leakage and cochlear implants are additional high-risk contexts. [51][354]
- ▸Reported meningitis after COVID-19 or varicella vaccination is rare and primarily supported by case reports or case series, which cannot establish incidence or causality. [217][218][219]
Prevention strategy
Prevention of meningitis depends primarily on vaccination, protection of high-risk individuals, rapid recognition of outbreaks, and surveillance of changing pathogen and serogroup patterns. The available evidence supports prevention directed at meningococcal, pneumococcal, Haemophilus influenzae type b, and selected viral causes, although the supplied studies do not establish a universal screening test for asymptomatic people. [355][357]
Meningococcal vaccination
MenAfriVac, a serogroup A conjugate vaccine, was introduced through preventive campaigns for people aged 1–29 years across the African meningitis belt and was followed by a marked decline in serogroup A epidemics. [186][357] Continued surveillance is necessary because serogroups C, W, and X and non-meningococcal pathogens remain important causes of disease after serogroup A control. [356]C[357]
NmCV-5 is a pentavalent conjugate vaccine targeting serogroups A, C, W, Y, and X. A phase 3 trial in Mali evaluated its safety and immunogenicity when co-administered with routine childhood vaccines at 9 and 15 months, compared with a licensed quadrivalent MenACWY conjugate vaccine. [190] Earlier randomized trials also evaluated MenA conjugate vaccine formulations administered with Expanded Programme on Immunization vaccines at 14–18 weeks, 9–12 months, and 12–18 months, supporting integration of meningococcal vaccination into routine infant immunization. [186]
For outbreak control, NmCV-5 was used in reactive campaigns in Niger during 2024 for outbreaks caused by serogroups C, W, and X; a matched case-control study assessed effectiveness against PCR-confirmed meningococcal meningitis in people aged 1–19 years who developed symptoms at least 10 days after the campaign. [356]C The study design illustrates the importance of post-campaign effectiveness evaluation, particularly where serogroup distribution is changing. [356]C[357]
Quadrivalent ACWY vaccination remains relevant where circulating serogroups, outbreaks, travel, or institutional exposure justify protection. In a phase 3 trial among Bangladeshi adults aged 18–45 years, a locally manufactured ACWY polysaccharide vaccine was compared with an approved comparator after a single subcutaneous dose, with follow-up through 3 months. [194] An Indian expert consensus reported 95.7–99.5% seroprotection with MenACWY conjugate vaccines, while emphasizing that disease burden is likely underestimated because of limited surveillance. [287]
Pneumococcal and targeted prevention
Pneumococcal conjugate vaccination reduces disease caused by vaccine serotypes, but replacement by non-vaccine serotypes remains a concern. [297]C In Taiwan, pneumococcal meningitis was assessed before and after introduction of PCV13 into the national childhood programme, emphasizing the need for continued microbiological surveillance after vaccine implementation. [297]C In children with sickle cell disease, pneumococcal immunization combined with antibiotic prophylaxis has reduced invasive pneumococcal disease, although meningitis risk remains higher than in the general population. [354]C
Children with cerebrospinal-fluid leakage or a cochlear implant require particular attention to pneumococcal prevention because meningeal breach and cochlear implantation are recognized risk contexts for bacterial meningitis. [51]D A French nationwide cohort specifically evaluated the epidemiology of meningitis in children with these conditions and the effect of PCV13-era prevention. [51]D Vaccination and prophylaxis should therefore be reviewed promptly in children with sickle cell disease, CSF leakage, or cochlear implants according to local immunization policy. [51]D[354]C
Surveillance and changing epidemiology
Post-vaccination surveillance remains essential because meningitis epidemiology changes after vaccine introduction. In Guinea during 2021–2024, surveillance examined suspected meningitis and compliant CSF sampling in the post-MenAfriVac era, when serogroup A declined and other meningococcal serogroups and pathogens became more prominent. [357] In Korea, adult community-acquired bacterial meningitis showed a decline in the proportion attributed to Streptococcus pneumoniae and a significant rise in Klebsiella pneumoniae during 2009–2023, illustrating that vaccination does not eliminate the need for pathogen surveillance. [236]D
Baseline incidence data are also important when evaluating vaccine safety. A prospective Ghanaian and Kenyan cohort measured meningitis, malaria, hospitalization, and mortality in children younger than 5 years before RTS,S/AS01E malaria-vaccine introduction. [222] Subsequent cluster-randomized implementation evaluation in Ghana, Kenya, and Malawi assessed feasibility, impact, safety signals, and previously reported imbalances involving meningitis, cerebral malaria, and mortality among girls. [195] RTS,S/AS01E is a malaria vaccine, not a meningitis vaccine, so its implementation should not be interpreted as meningitis prevention. [195][222]
Vaccine safety and post-vaccination events
Meningitis reported after vaccination is uncommon and requires clinical investigation rather than automatic attribution to the vaccine. A systematic review identified 35 cases after COVID-19 vaccination, including 12 with proven viral diagnoses and 23 reported as vaccine-induced, while another review included 31 patients from 27 reports; headache and fever were common presentations. [217][219] These reports establish a safety signal requiring assessment but cannot determine incidence or causality. [217][219]
Rare cases of varicella vaccine-associated meningitis have also been reported in immunocompetent children and adolescents; a review identified 15 cases, with a median age of 11 years, despite the vaccine’s overall excellent safety record. [218] After EV71 vaccination, a retrospective pediatric study found no significant increase in clinical severity among EV71-associated meningoencephalitis compared with disease caused by other enterovirus subtypes, although most cases were caused by non-EV71 or unclassified enteroviruses. [328]
Screening and public-health priorities
The supplied evidence supports risk-based prevention and epidemiological surveillance rather than routine screening of asymptomatic individuals. Priority activities are maintaining age-appropriate routine vaccination, using targeted meningococcal vaccination during outbreaks or for defined risk groups, ensuring pneumococcal protection in high-risk children, and monitoring CSF-confirmed disease, serogroups, serotypes, and emerging pathogens. [51]D[186][287][297]C[354]C[356]C[357]
| Population or setting | Prevention priority | Evidence |
|---|---|---|
| African meningitis belt | MenA vaccination and surveillance for C, W, X, and other pathogens | [186][356]C[357] |
| Infants in routine immunization programmes | Consider integrated meningococcal vaccination; NmCV-5 was studied at 9 and 15 months | [190][186] |
| Outbreak settings | Reactive vaccination and post-campaign effectiveness assessment | [356]C |
| Sickle cell disease | Pneumococcal vaccination plus antibiotic prophylaxis | [354]C |
| CSF leakage or cochlear implant | Review pneumococcal prevention and maintain specialist follow-up | [51]D |
| Vaccine safety monitoring | Investigate post-vaccination meningitis clinically and microbiologically | [217][218][219] |
Guidelines and Resources
- ▸Treat suspected acute bacterial meningitis as an emergency; hospital assessment and treatment should be rapid, and antimicrobial therapy should not be delayed beyond **3 hours** for imaging or LP. [248][259]
- ▸Start empirical antituberculosis therapy promptly when TBM is suspected rather than waiting for microbiological or molecular confirmation. [258]
- ▸Use the 2025 international TBM guideline for current recommendations spanning diagnosis, chemotherapy, adjunctive anti-inflammatory therapy, and neurocritical or neurosurgical care. [239]
- ▸Consider herpes simplex encephalitis when clinically appropriate and avoid treatment delays beyond **48 hours after admission**. [252][253]
- ▸Use pregnancy, neonatal, neurocritical-care, vaccine-prevention, anthrax, Lyme, and autoimmune-disease resources according to the clinical context rather than as substitutes for a core meningitis pathway. [241][243][247][249][254][255][257]
Core acute meningitis guidance
Acute meningitis is a medical emergency requiring rapid hospital assessment, timely diagnostic investigation, and prompt treatment when bacterial disease is suspected. The UK joint specialist-societies guideline addresses diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults and was developed because bacterial meningitis and meningococcal sepsis remain uncommon but have high case-fatality rates; it emphasizes that early recognition and prompt treatment improve survival. [248] The EFNS guideline similarly recommends rapid hospital admission and assessment for lumbar puncture (LP) when clinically safe; neuroimaging may be performed before LP, but antimicrobial therapy should not be delayed beyond 3 hours. [259]
The older UK guidance for suspected viral encephalitis remains relevant when encephalitis is in the differential. Adult and paediatric national guidelines emphasize early recognition and treatment of herpes simplex encephalitis because delayed aciclovir therapy—particularly delay beyond 48 hours after hospital admission—is associated with worse prognosis. [252][253] These encephalitis guidelines should be used alongside, rather than as a substitute for, acute bacterial meningitis pathways when meningitis is possible. [248][252][253]
Tuberculous meningitis
Tuberculous meningitis (TBM) is the most severe form of tuberculosis and causes death or disability in approximately half of affected patients. [239] The 2025 international clinical practice guideline was developed by the Tuberculous Meningitis International Research Consortium, with representation from India, Indonesia, South Africa, Uganda, Viet Nam, Australia, the Netherlands, the UK, and the USA. [239] Its scope includes TBM diagnosis, antituberculosis chemotherapy, adjunctive anti-inflammatory treatment, and neurocritical and neurosurgical care. [239]
The earlier British Infection Society guideline describes TBM as a medical emergency and recommends starting empirical antituberculosis treatment promptly when TBM is suspected rather than waiting for microbiological or molecular confirmation. [258] It identifies LP with cerebrospinal-fluid (CSF) examination as the principal diagnostic approach and also covers central nervous-system tuberculosis in children and adults, including intracerebral tuberculoma without meningitis and spinal-cord tuberculosis. [258] The 2025 guideline should take precedence as the more current international resource, while the 2009 guidance remains a historical and practical reference. [239][258]
Pathogen- and syndrome-specific resources
For Lyme neuroborreliosis, the EFNS guideline recommends that definite disease be supported by neurological symptoms, CSF pleocytosis, and intrathecal Borrelia burgdorferi sensu lato-specific antibody production; two of these criteria support possible disease. [257] CSF PCR and culture may provide corroboration when symptom duration is less than 6 weeks, but PCR is otherwise not recommended in that guideline. [257] The American Academy of Neurology treatment parameter is marked retired; it reviewed antimicrobial treatment, manifestation-specific regimens, treatment duration, and post-Lyme syndrome, and concluded that nervous-system Lyme disease responds to antimicrobial therapy, although its recommendations should not be treated as current standalone guidance. [260]
Neurocritical care resources are relevant when meningitis is complicated by cerebral oedema or raised intracranial pressure. The Neurocritical Care Society guideline evaluates hyperosmolar agents, including mannitol and hypertonic saline, corticosteroids, and selected non-pharmacological therapies, while emphasizing the need to balance efficacy with safety. [243] It is a supportive-care resource rather than a meningitis-specific antimicrobial guideline. [243]
Special populations and exposure-related resources
Pregnancy requires consideration of preventable and vertically transmitted infections. The 2025 US Preventive Services Task Force reaffirmation recommends screening for syphilis during pregnancy because untreated infection can cause congenital syphilis, which is associated with prematurity, low birth weight, stillbirth, neonatal death, and neurological abnormalities including meningitis. [241] Intraamniotic infection can result in neonatal pneumonia, meningitis, sepsis, and death; the American College of Obstetricians and Gynecologists provides intrapartum-management guidance for affected patients. [245][246] Pregnant patients with presumptive exposure to Listeria monocytogenes require obstetric assessment because maternal listeriosis may be nonspecific, whereas fetal and neonatal infection can cause pregnancy loss, preterm labour, neonatal sepsis, meningitis, and death. [251]
For neonatal research and surveillance, the GAIA/Brighton Collaboration resource provides standardized case definitions for neonatal bloodstream infection, meningitis, and lower respiratory tract infection to support comparable data collection, analysis, and presentation in maternal-immunization safety studies. [247] For congenital spinal dysraphism, the Congress of Neurological Surgeons guideline evaluates whether myelomeningocele closure within 48 hours reduces wound infection or ventriculitis; this is a neurosurgical infection-prevention resource, not a treatment guideline for acquired meningitis. [244] Pediatric hydrocephalus guidance addresses posthaemorrhagic hydrocephalus in premature infants and evaluates treatment strategies using an evidence-based literature review. [250]
Anthrax guidance is relevant to meningitis occurring during naturally acquired or bioterrorism-related anthrax and to mass-casualty preparedness. The CDC clinical framework addresses diagnosis and treatment in conventional settings and the use of medical countermeasures after a potential aerosolized Bacillus anthracis release. [249] Anthrax vaccine recommendations from ACIP cover epidemiology, vaccine effectiveness, immunogenicity, safety, and pre-event or pre-exposure use of anthrax vaccine adsorbed. [256]
Pneumococcal prevention is addressed in the ACIP recommendation for PPSV23, which targets invasive pneumococcal disease, including bacteraemia and meningitis, among adults aged 65 years or older and younger adults with medical conditions associated with increased risk. [254] Neuropsychiatric systemic lupus erythematosus guidance covers diagnosis, prevention, monitoring, and treatment of neurological manifestations such as seizures, cerebrovascular disease, cognitive dysfunction, acute confusional state, psychosis, and peripheral nervous-system disease; these conditions may complicate the differential diagnosis of meningitis or encephalitis. [255]
| Clinical context | Principal resource | Scope |
|---|---|---|
| Acute meningitis and meningococcal sepsis | UK joint specialist-societies guideline | Diagnosis and management in immunocompetent adults [248] |
| Community-acquired bacterial meningitis | EFNS guideline | Initial management, investigations, antibiotics, and supportive therapy [259] |
| Tuberculous meningitis | 2025 international guideline | Diagnosis, antituberculosis chemotherapy, adjunctive anti-inflammatory therapy, and neurocritical/neurosurgical care [239] |
| Suspected viral encephalitis | British adult and paediatric guidelines | Recognition and early management, including aciclovir treatment [252][253] |
| Cerebral oedema or raised intracranial pressure | Neurocritical Care Society guideline | Hyperosmolar therapy, corticosteroids, and selected non-pharmacological treatment [243] |
| Lyme neuroborreliosis | EFNS guideline; AAN parameter retired | Diagnostic criteria and historical treatment evidence [257][260] |
| Pregnancy, neonates, and prevention | USPSTF, ACOG, GAIA/Brighton, ACIP | Syphilis, intraamniotic infection, neonatal definitions, and pneumococcal prevention [241][245][246][247][254] |
| Special infections and neurosurgery | CDC/ACIP anthrax resources; CNS myelomeningocele and hydrocephalus guidelines | Anthrax preparedness, closure timing, and posthaemorrhagic hydrocephalus [244][249][250][256] |
References
- [1]
Håndstad M, Alaoui-Ismaili A, Juhler M et al.. “A systematic review of reviews on ventriculostomy related infection definitions: A fundamental problem.” Neurosurgical review (2025). PMID: 40069523 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [2]
Vaezipour N, Bigi S, Song R et al.. “Rifampicin and its neuroprotective properties in humans - A systematic review.” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2025). PMID: 40024057 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [3]
Taweephol T, Pongpitakmetha T, Boonwan N et al.. “Clinical characteristics and factors associated with tuberculous meningitis outcomes in Thailand: A 13-year retrospective cohort study.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 41173203 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification, Epidemiology and Risk Factors, Prognosis and Long-term Outcomes, Special Populations - [4]
Kane Y, Nalikka B, Tendu A et al.. “Genetic Diversity and Geographic Spread of Henipaviruses.” Emerging infectious diseases (2025). PMID: 40023785 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [5]
Long B, Gottlieb M. “Emergency medicine updates: Evaluation and diagnosis of sepsis and septic shock.” The American journal of emergency medicine (2025). PMID: 39892181 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [6]
Sultana S, Islam A, Ng J et al.. “Bat Reovirus as Cause of Acute Respiratory Disease and Encephalitis in Humans, Bangladesh, 2022-2023.” Emerging infectious diseases (2025). PMID: 41490742 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [7]
Vernygora O, Bourque L, Jones M et al.. “Novel Dolphin Tupavirus from Stranded Atlantic White-Sided Dolphin with Severe Encephalitis, Canada, 2024.” Emerging infectious diseases (2025). PMID: 41379633 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [8]
Zhu Z, Bao Y, Zhang Z et al.. “Emerging Neisseria meningitidis ST-1466 and ST-11026 as urogenital pathogens in China.” BMC infectious diseases (2025). PMID: 41162927 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [9]
Gass JT, Nofchissey RA, Twohig FM et al.. “Discovery of a novel lymphocytic choriomeningitis virus strain associated with severe human disease in immunocompetent patient, New Mexico.” Emerging microbes & infections (2025). PMID: 40838561 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification, Epidemiology and Risk Factors - [10]
Neri A, Taviani E, Ferraro F et al.. “Genomic analysis of Neisseria meningitidis serogroup W causing invasive meningococcal disease in four travellers from Saudi Arabia, Italy, 2025.” Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin (2025). PMID: 40776895 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [11]
Cherabuddi K, Tagliamonte MS, Lednicky JA et al.. “A Case Cluster of Aseptic Meningitis Associated With a Newly Identified Recombinant Echovirus 6/Coxsackievirus B1 Enterovirus.” The Journal of infectious diseases (2025). PMID: 40359283 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [12]
Garijo-Toledo M, Alarcón-Elbal PM, Montero E et al.. “Mortality associated with Angiostrongylus cantonensis in non-human primates in Europe.” International journal for parasitology (2025). PMID: 40194692 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [13]
Jiang Y, Yang J, Liu Y et al.. “A neonate with meningitis caused by probiotic-related Clostridium butyricum.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 40185197 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [14]
Ewing A, Haldeman S, Job MJ et al.. “Haemophilus influenzae Type b Meningitis in Infants, New York, New York, USA, 2022-2023.” Emerging infectious diseases (2025). PMID: 40023813 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [15]
Chiu CY, Godasi RR, Hughes HR et al.. “Two Human Cases of Fatal Meningoencephalitis Associated with Potosi and Lone Star Virus Infections, United States, 2020-2023.” Emerging infectious diseases (2025). PMID: 39983710 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [16]
Leiva-Ordoñez JE, Quintero B. “Diagnosis of Tuberculous Meningitis: Integrating Clinical Assessment and Molecular Diagnostics.” Diagnostics (Basel, Switzerland) (2026). PMID: 41750700 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [17]
Trejos Pino JV, Rodriguez Delgado JC. “Clinical Presentations and Nosocomial Infections of Neurolisteriosis.” The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale (2025). PMID: 40547324 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [18]
Ciftci E, Ocal D, Somer A et al.. “Current methods in the diagnosis of invasive meningococcal disease.” Frontiers in pediatrics (2025). PMID: 40330073 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [19]
Scheier TC, Tufa TB, Feldt T et al.. “Standard of care in advanced HIV disease: review of HIV treatment guidelines in sub-Saharan African countries-an extension study of eight countries.” AIDS research and therapy (2025). PMID: 40158188 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [20]
Zhu W, Shao L, Feng S et al.. “Tahyna virus: an emerging threat to public health.” Archives of virology (2025). PMID: 39928175 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [21]
Wu LL, Shi WD, Peng WF et al.. “Unraveling the interplay between meningitis and mitochondria: Etiology, pathogenesis, and therapeutic insights.” International immunopharmacology (2025). PMID: 39765004 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [22]
Kneubehl AR, Rehm DP, Curtis MW et al.. “Geographically Distinct Circulation of Genotype II and III St. Louis Encephalitis Virus, Texas, USA, 2009-2024.” Emerging infectious diseases (2026). PMID: 41986946 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [23]
Andrus PS, Han QC, Yang LM et al.. “Population genetic diversity of invasive Pomacea snails and surveillance of Angiostrongylus cantonensis in Shanghai, East China.” Parasites & vectors (2026). PMID: 41803893 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [24]
Yang H, Wang H, Han J et al.. “Emergence of a novel cefotaxime- and ciprofloxacin-resistant strain of serogroup Y Neisseria meningitidis sequence type 23 clonal complex in China.” The Journal of infection (2026). PMID: 41724334 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [25]
Gonzales BE, Durand D, Mercado EH et al.. “Genomic features of pneumococcal strains isolated from paediatric patients with invasive disease during pneumococcal conjugate vaccine introduction in Lima, Peru.” Microbial genomics (2026). PMID: 41632608 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [26]
Itani TM, Chalapa VI, Patrusheva AK et al.. “Genetic Diversity of the Non-Polio Enteroviruses Detected in Samples of Patients with Aseptic Meningitis in the Ural Federal District and Western Siberia.” Viruses (2026). PMID: 41600882 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [27]
Aparicio MT, Diop S, Mounier R. “Comments on: risk factors for nosocomial meningitis in patients with external ventricular drainages.” Journal of intensive care (2026). PMID: 41588552 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [28]
Andersen M, Haglund A, Murra M et al.. “Validation of the ICD-10 Diagnoses of Early-Onset Neonatal Infection in the Danish National Patient Register from 2010 to 2018.” Clinical epidemiology (2026). PMID: 41541820 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [29]
Fratty IS, Kriger O, Weiss L et al.. “Epidemiology of Enteroviruses Among Hospitalized Patients in Israel (2016-2024): CNS Involvement, Subtype Variability, and Seasonality.” Journal of medical virology (2026). PMID: 41540956 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [30]
Liao H, Li M, Zeng L et al.. “Molecular characterization of Neisseria meningitidis isolates from healthy individuals in Meigu County, Sichuan Province, 2021-2024.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 41518555 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [31]
Pu J, Wu S, He JQ. “High dose of rifampicin in the treatment of tuberculous meningitis: a systematic review and meta-analysis of randomized controlled trials.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 41511673 ↗
L1aSR_MA_RCTCited in: Epidemiology and Risk Factors, Management, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence - [32]
Matmat K, Jamann H, Maazouzi A et al.. “A multidimensional analysis of neuropsychiatric lupus: clinical, biological and imaging insights from systematic evidence.” Frontiers in immunology (2026). PMID: 41918728 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [33]
Alviz LF, Kim CY, Monette LE et al.. “Detection of sequelae from acute meningitis during clinical review by a healthcare provider: a systematic review and meta-analysis.” BMC medicine (2026). PMID: 41761295 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [34]
Alviz LF, Kim CY, Benevides-Tadinac AC et al.. “Detection of hearing loss by formal audiological testing after acute infectious meningitis: a global systematic review and meta-analysis.” BMC medicine (2026). PMID: 41761238 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, History and Physical Examination, Diagnosis and Workup, Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [35]
Lazarus G, Caddey B, Dean A et al.. “Antimicrobial resistance in bacterial meningitis caused by Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae (2010-24): a systematic review and meta-analysis.” The Lancet. Microbe (2026). PMID: 41616789 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Diagnosis and Workup, Management - [36]
Onohuean H, Choonara YE. “Epidemiological distribution of bacterial meningitis infections in South Africa: a systematic review and meta-analysis.” BMC infectious diseases (2025). PMID: 41073968 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [37]
Akwetey SA, Osman AH, Kotey FCN et al.. “The epidemiology of infectious meningitis in Ghana: a systematic review and meta-analysis.” BMC public health (2025). PMID: 40770623 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [38]
Ellis J, Groppelli E, Doyle R et al.. “Epstein-Barr virus and cytomegalovirus co-infections and mortality risk in patients with HIV-associated cryptococcal meningitis: a post-hoc analysis of a prospective nested cohort in the AMBITION-cm randomised controlled trial.” The lancet. HIV (2025). PMID: 40915307 ↗
L1bRCTCited in: Epidemiology and Risk Factors, Landmark Trials and Key Evidence, Special Populations - [39]
Rutakingirwa MK, Skipper CP, Dai B et al.. “Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 40795226 ↗
L2bTRIAL_NONRANDOMCited in: Epidemiology and Risk Factors, Special Populations - [40]
Verma R, Chakraborty R. “A Clinico-Immunological Perspective of Paradoxical Reaction in HIV-ve Tuberculous Meningitis with Therapeutic Possibilities.” Neurology India (2025). PMID: 40705281 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Supportive Care and Complication Management, Special Populations - [41]
Liechti FD, Drost EHGM, Bijlsma MW et al.. “Brain Abscesses Complicating Bacterial Meningitis-A Nationwide Cohort Study From the Netherlands.” European journal of neurology (2026). PMID: 41738138 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Differential Diagnosis - [42]
Xu X, Su X, Li W et al.. “Clinical features and mortality risk factors in non-HIV elderly patients with cryptococcal meningitis: A retrospective cohort study from 2013 to 2022.” PLoS neglected tropical diseases (2025). PMID: 40934274 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [43]
Kim E, Hong J, Shin H et al.. “Prophylactic antibiotic use in closed basilar skull fractures: A nationwide cohort study.” The journal of trauma and acute care surgery (2026). PMID: 40857668 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [44]
Drummond H, Umana E, Mills C et al.. “Prevalence of invasive bacterial infection among febrile infants with positive urinalysis results: a planned secondary analysis of the Febrile Infants Diagnostic assessment and Outcome (FIDO) prospective observational cohort study.” Archives of disease in childhood (2025). PMID: 40628460 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, History and Physical Examination, Special Populations - [45]
He L, Yu M, Sun Z et al.. “Dynamic analysis of pathogenic distribution and drug resistance mechanism in neonatal suppurative meningitis: a retrospective study.” Italian journal of pediatrics (2025). PMID: 40604892 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [46]
Alhajaji R, Alfahmi M, Alamri SA et al.. “Neisseria Meningitidis Carriage Among Hajj and Umrah Pilgrims: A Systematic Review and Meta-Analysis.” European journal of medical research (2025). PMID: 40765002 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Prevention and Screening - [47]
Ali F, Imperial M, Morshed M et al.. “Pediatric Meningoencephalitis Cluster Caused by Snowshoe Hare Virus, Whistler, British Columbia, Canada, 2024.” Emerging infectious diseases (2026). PMID: 41986254 ↗
L4CASE_REPORTCited in: Epidemiology and Risk Factors, Differential Diagnosis - [48]
Szojka ZI, Florian DM, Cabal A et al.. “Imported aseptic meningitis due to Toscana virus infection in Austria since 2006, including a case series from 2023.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 41615838 ↗
L4CASE_REPORTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Diagnosis and Workup, Differential Diagnosis - [49]
Lagare A, Abdoulaye B, Thiaw FD et al.. “First detection of echovirus 18 associated with aseptic meningitis in a child in Niger Republic, 2024: a case report.” BMC infectious diseases (2025). PMID: 41126107 ↗
L4CASE_REPORTCited in: Epidemiology and Risk Factors - [50]
Li Y, Zhang X, Wang M et al.. “Observation on the efficacy of Xiao Chai Hu Tang plus minus Tang combined with sodium valproate in the treatment of meningitis-associated epilepsy.” Pakistan journal of pharmaceutical sciences (2025). PMID: 40761063 ↗
L1bRCTCited in: Epidemiology and Risk Factors - [51]
Levy C, Bizot E, Milcent K et al.. “Epidemiology and Characteristics of Bacterial Meningitis of Children with Cerebrospinal Fluid Leakage or Cochlear Implant.” Journal of the Pediatric Infectious Diseases Society (2026). PMID: 41800559 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Pathophysiology, History and Physical Examination, Diagnosis and Workup, Prevention and Screening - [52]
Lykke MR, Sørensen HT, Lawn JE et al.. “School performance following invasive Group B Streptococcus disease in early infancy in Denmark.” Annals of epidemiology (2026). PMID: 41643755 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Special Populations - [53]
Hawkins PA, Chochua S, Prasad N et al.. “Group A Streptococcus Meningitis, United States, 1997-2022.” Emerging infectious diseases (2026). PMID: 41612532 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Differential Diagnosis, Special Populations - [54]
André A, Brière O, Bourreau L et al.. “Risk factors for acute kidney injury associated with intravenous acyclovir in older adults: ACICLOAGED study.” Maturitas (2026). PMID: 41604824 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Differential Diagnosis - [55]
Mehl C, Schmidt-Chanasit J, Becker-Ziaja B et al.. “Lymphocytic Choriomeningitis Virus Seroprevalence in a Cohort of German Forestry Workers.” Viruses (2025). PMID: 41600769 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [56]
Anjum SH, Hargarten J, Dulek B et al.. “Cerebral Venous Thrombosis in Previously Healthy Patients with Cryptococcal Meningitis.” The Journal of infectious diseases (2026). PMID: 41443253 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [57]
Mesele DW, Kalayu AA, Teshome S et al.. “Enhanced detection of bacterial etiologies, antibiotic resistance profile, and treatment outcomes of meningitis patients in Ethiopia: a prospective cross-sectional study.” BMC microbiology (2025). PMID: 41387772 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [58]
Lambebo IH, Eba K, Tucho GT. “Association between climatic conditions and infectious diseases: implications for Central Ethiopia region.” BMC infectious diseases (2025). PMID: 41331557 ↗
L5OTHERCited in: Epidemiology and Risk Factors, History and Physical Examination - [59]
Meya DB, Cresswell FV, Dai B et al.. “Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis.” The New England journal of medicine (2025). PMID: 41406445 ↗
L1bRCTCited in: Etiology and Triggering Factors, Management, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence, Special Populations - [60]
Burstein B, Waterfield T, Umana E et al.. “Prediction of Bacteremia and Bacterial Meningitis Among Febrile Infants Aged 28 Days or Younger.” JAMA (2026). PMID: 41359314 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors, History and Physical Examination, Management, Special Populations - [61]
Singh MP, Yadav R, Singh J. “Drug-Induced Aseptic Meningitis: A 25-Year Systematic Review of Case Reports.” Clinical neuropharmacology (Unknown). PMID: 41529234 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors, Pathophysiology, Management - [62]
Liang A, Zhang Y, Li X et al.. “Association of the blood urea nitrogen to serum albumin ratio on prognosis in patients with bacterial meningitis: a retrospective cohort study.” Frontiers in cellular and infection microbiology (2026). PMID: 41929452 ↗
L2bCOHORTCited in: Etiology and Triggering Factors, Diagnosis and Workup, Prognosis and Long-term Outcomes - [63]
Dzięgiel M, Głodowicz Z, Jóźwiak A et al.. “Bacterial meningitis in adults: therapeutic challenges in the era of antibiotic resistance and the potential of bacteriophages and associated by products.” Frontiers in cellular and infection microbiology (2026). PMID: 41728112 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Management - [64]
Scott TL, Quezado M, Williamson PR. “Update on the diagnosis, pathophysiology and treatment strategies in non-HIV-associated cryptococcal meningoencephalitis.” Expert review of anti-infective therapy (2026). PMID: 41661810 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology, Special Populations - [65]
Shi Y, Liang T, Shi C et al.. “Molecular mechanisms of streptococcal disruption of the blood-brain barrier and their pathogenic role in bacterial meningitis.” Frontiers in immunology (2025). PMID: 41573555 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology - [66]
Churcher LM, Bartlett AW, Pendle S et al.. “Impact of the BioFire FilmArray Meningitis-Encephalitis Panel on Management of Suspected Paediatric Central Nervous System Infections: A Single-Centre Retrospective Cohort Study.” Journal of paediatrics and child health (2026). PMID: 41652807 ↗
L2bCOHORTCited in: Etiology and Triggering Factors, Pathophysiology, Diagnosis and Workup, Differential Diagnosis, Prognosis and Long-term Outcomes - [67]
Maeda A, Hayashi K, Izumi R et al.. “Lumbar-peritoneal shunt-associated meningitis and peritoneal abscess due to Corynebacterium striatum: A case report and literature review.” Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2026). PMID: 41391636 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, Supportive Care and Complication Management - [68]
Ba A, Wang L, Ren R et al.. “Purulent meningitis in X-linked agammaglobulinemia: one case report.” Frontiers in immunology (2026). PMID: 41988175 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [69]
Hariswar PT, Mahathi G, Praveenkumar T et al.. “Clinical Reasoning: A 49-Year-Old Man With Meningoencephalitis and Persistent Altered Mental Status.” Neurology (2026). PMID: 41771008 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, History and Physical Examination, Diagnosis and Workup - [70]
Grant A, Keegan S, Kulasegaram R. “Role of long-acting injectables in perinatally acquired HIV, with persistent viraemia and non-nucleoside reverse transcriptase inhibitor resistance.” Sexually transmitted infections (2026). PMID: 41545056 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, Diagnosis and Workup, Management, Special Populations - [71]
Li XF, Ker A, Liao HL et al.. “Adult-onset Still's disease presenting with aseptic meningitis: a case report.” Frontiers in immunology (2025). PMID: 41476957 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, Management, Supportive Care and Complication Management - [72]
Krebs L, Durden B, Saguil A. “Aseptic and Bacterial Meningitis: Diagnosis, Treatment, and Prevention.” American family physician (2026). PMID: 41839077 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology - [73]
Tucker EW, Kim J, Erice C et al.. “Host-directed nanotherapy for the treatment and imaging of tuberculous meningitis.” Theranostics (2026). PMID: 41993622 ↗
L5OTHERCited in: Etiology and Triggering Factors, Pathophysiology, Diagnosis and Workup, Management - [74]
Pircher H, Thomas OS, Haefke AS et al.. “Increased Constitutive Interferon-β Levels and Altered CD4 T Cell Homeostasis Induced by Expression of a Viral Glycoprotein.” European journal of immunology (2026). PMID: 41972454 ↗
L5OTHERCited in: Etiology and Triggering Factors - [75]
Flannery DD, Cossaboom CM, Flietstra TD et al.. “Lymphocytic Choriomeningitis Virus Seroprevalence among Urban Pregnant Women and Newborns, Philadelphia, Pennsylvania, USA, 2021.” Emerging infectious diseases (2026). PMID: 41863505 ↗
L5OTHERCited in: Etiology and Triggering Factors, Special Populations - [76]
Kansas GS. “Transient loss of KLF2 expression is essential for CD8 effector T cell expansion.” Journal of immunology (Baltimore, Md. : 1950) (2026). PMID: 41847849 ↗
L5OTHERCited in: Etiology and Triggering Factors, Diagnosis and Workup - [77]
Wang Y, Liu H, Wang Y et al.. “Biosynthesis of a Polysaccharide-based Glycoconjugate Vaccine against Neonatal Meningitis-Causing Escherichia coli O45.” ACS synthetic biology (2026). PMID: 41779879 ↗
L5OTHERCited in: Etiology and Triggering Factors, Prevention and Screening - [78]
George LS, Chakraborty A, Gupta S et al.. “Implementation of India's largest sentinel surveillance for meningitis: an exploratory qualitative analysis of the facilitators and challenges in this sentinel site network.” Frontiers in public health (2026). PMID: 41778120 ↗
L5OTHERCited in: Etiology and Triggering Factors, Prognosis and Long-term Outcomes, Prevention and Screening - [79]
Lux J, Erhardt M, Rechsteiner L et al.. “Synthetic peptide V11A reduces bacterial load and inflammation in pneumococcal meningitis.” Frontiers in cellular and infection microbiology (2025). PMID: 41737843 ↗
L5OTHERCited in: Etiology and Triggering Factors, Management - [80]
Charmoy M, Maier JM, Wyss T et al.. “Memory-like CD8+ T cells lacking PD-1 adapt to persistent stimulation by reducing TCR signal transduction rather than increasing exhaustion.” Frontiers in immunology (2026). PMID: 41727489 ↗
L5OTHERCited in: Etiology and Triggering Factors - [81]
Yabumoto T, Sugiyama S, Hosokawa A et al.. “Viral load and pathophysiology-based framework in varicella-zoster virus meningitis: Focus on altered consciousness and outcomes.” Journal of the neurological sciences (2026). PMID: 41690184 ↗
L5OTHERCited in: Etiology and Triggering Factors, History and Physical Examination - [82]
Wollenweber ML, Beyrer K, Baillot A et al.. “The Meningitis and Encephalitis Registry of Lower Saxony, Germany (MERIN) - design and main results of circulating neurotropic pathogen surveillance, 2003 to 2023.” Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin (2026). PMID: 41684324 ↗
L5OTHERCited in: Etiology and Triggering Factors, Differential Diagnosis, Special Populations - [83]
Huang M, Wang Y, Chen T et al.. “Evaluation of contezolid's cerebrospinal fluid concentration and safety in tuberculous meningitis patients.” Microbiology spectrum (2026). PMID: 41823550 ↗
L1bRCTCited in: Pathophysiology, Diagnosis and Workup, Management, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence - [84]
Donovan J, Duc Bang N, Dong HKT et al.. “Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial.” Nature medicine (2026). PMID: 41540106 ↗
L1bRCTCited in: Pathophysiology, Management, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence - [85]
Santiago IB, da Silva AA, Nóbrega ILP et al.. “Leukodystrophy-like phenotype in early-onset neuropsychiatric systemic lupus erythematosus: Case series and systematic review of the literature.” Revue neurologique (2026). PMID: 41638970 ↗
L2aSR_OBSCited in: Pathophysiology, Diagnosis and Workup, Supportive Care and Complication Management - [86]
Muyidi AA, Al-Zaydani IA, Alzahrani SJ et al.. “Neonatal invasive meningococcal disease: Clinical case from Saudi Arabia and updated review of reported cases.” Journal of infection and public health (2026). PMID: 41894900 ↗
L4CASE_REPORTCited in: Pathophysiology, Diagnosis and Workup, Management, Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations - [87]
Luo Y, Guo Y, Zhu Y et al.. “Differentiating scrub typhus meningitis from brucellar meningitis in children: A single-center retrospective study.” PLoS neglected tropical diseases (2026). PMID: 41824464 ↗
L2bCOHORTCited in: Pathophysiology, Diagnosis and Workup - [88]
Chouksey SS, Singh VK, Chaurasia RN et al.. “Neurocognitive Outcomes and Their Correlation with Brain-Based Biomarkers in Tuberculous Meningitis: A Prospective Study.” The American journal of tropical medicine and hygiene (2026). PMID: 41666470 ↗
L2bCOHORTCited in: Pathophysiology, Diagnosis and Workup, Prognosis and Long-term Outcomes - [89]
Wong EWN, Chan CF, Chan PS. “Ocular Manifestations of Biopsy-Proven B Virus Infection with Central Nervous System Involvement.” JAMA ophthalmology (2026). PMID: 41712248 ↗
L4CASE_REPORTCited in: Pathophysiology, Diagnosis and Workup - [90]
Bao Y, Zhang W, Liu X et al.. “Case Report: Complete remission of Guillain-Barré syndrome in neuropsychiatric lupus with telitacicept.” Frontiers in immunology (2026). PMID: 41659868 ↗
L4CASE_REPORTCited in: Pathophysiology, Diagnosis and Workup, Management, Prognosis and Long-term Outcomes - [91]
Yang X, Li Z, Dai X et al.. “Streptococcus pyogenes and EBV coinfection in severe adult meningoencephalitis: a rare diagnosis in a diabetic patient.” Frontiers in cellular and infection microbiology (2025). PMID: 41625152 ↗
L4CASE_REPORTCited in: Pathophysiology, Diagnosis and Workup, Management - [92]
Ye R, Guo K, Zhou D et al.. “Misdiagnosed tuberculous myelitis turned out to be spinal malignant peripheral nerve sheath tumor: a case report.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 41521307 ↗
L4CASE_REPORTCited in: Pathophysiology - [93]
Liu F, Sun S, Zhang Y et al.. “Possible tuberculous meningitis presenting with predominant voiding dysfunction in an elderly patient: A case report.” Journal of infection and public health (2026). PMID: 41505815 ↗
L4CASE_REPORTCited in: Pathophysiology, Management - [94]
Ito Y, Hoeltermann TA, Anjum S et al.. “Corticosteroid Therapy and Long-Term Outcomes of Post-Infectious Inflammatory Syndrome in Non-HIV Immunosuppressed Cryptococcal Meningitis: A Multicenter Case Series.” The Journal of infectious diseases (2026). PMID: 41486473 ↗
L4CASE_REPORTCited in: Pathophysiology, Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations - [95]
Nagata W, Ishizuka T. “Pathogenesis and therapeutic strategies for neuropsychiatric lupus centered on innate immune activation.” Human cell (2026). PMID: 41989680 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [96]
Demirtzoglou G, Damanaki A, Flouda S et al.. “Unique brain mechanisms in early events in SLE with diffuse neuropsychiatric disease (NPSLE): Implications for the management.” Lupus (2026). PMID: 41831216 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [97]
Butler HM, Zehntner ME, Van Beusecum JP. “Endothelial Dysfunction: Insights into Systemic Lupus Erythematosus-associated Cardiovascular Disease and Neuropsychiatric Manifestations.” Journal of cardiovascular translational research (2026). PMID: 41795008 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [98]
Perera N, Gunawardena C, Abeyratne V et al.. “Neuroleptospirosis in patients presenting with primary central nervous system infection: A multicentre study.” PLoS neglected tropical diseases (2026). PMID: 41945620 ↗
L5OTHERCited in: Pathophysiology, Diagnosis and Workup, Differential Diagnosis, Supportive Care and Complication Management - [99]
Molloy CT, Alwarawrah Y, Cohen JA et al.. “Irgm1 Restrains CD8+ T Cell Cytokine Production and Apoptosis via Cell-Extrinsic Regulation of Type I Interferon Signaling.” European journal of immunology (2026). PMID: 41906618 ↗
L5OTHERCited in: Pathophysiology - [100]
Matmat K, Guéant-Rodriguez RM, Darcq E et al.. “IFNγ-associated immune-metabolic remodeling is linked to serotonin-kynurenine imbalance and cortical vulnerability in lupus-prone mice.” Frontiers in immunology (2026). PMID: 41869319 ↗
L5OTHERCited in: Pathophysiology - [101]
Onita T, Ikawa K. “Cerebrospinal Pharmacokinetic and Pharmacodynamic Evaluation of Sulbactam: Dosing Considerations for Acinetobacter baumannii Meningitis in Pediatric Patients.” Journal of the Pediatric Infectious Diseases Society (2026). PMID: 41810872 ↗
L5OTHERCited in: Pathophysiology, Diagnosis and Workup, Management, Special Populations - [102]
Yovel G, Packard JE, Wang JC et al.. “Neonatal CNS Human Parechovirus Infections in Western Pennsylvania in the 2024 Season.” Journal of medical virology (2026). PMID: 41810583 ↗
L5OTHERCited in: Pathophysiology, Diagnosis and Workup, Special Populations - [103]
Chen J, Cui C, Xu F et al.. “ShenQi DiHuang Decoction (SQDHD) Ameliorates Neuroinflammation and Neuropsychiatric Manifestations in Pristane Induced Lupus Mice via Blocking JAK1-STAT3 Pathway.” CNS neuroscience & therapeutics (2026). PMID: 41795136 ↗
L5OTHERCited in: Pathophysiology - [104]
Shean RC, Tardif KD, Rangel A et al.. “Evaluation of the Ultima Genomics UG 100 sequencer for low-cost, high-sensitivity metagenomic pathogen detection from cerebrospinal fluid.” Microbiology spectrum (2026). PMID: 41778823 ↗
L5OTHERCited in: Pathophysiology, Diagnosis and Workup, Differential Diagnosis - [105]
Twito NA, Röthlisberger AB. “Retrospective evaluation of leflunomide as second-line immunosuppressive therapy in dogs with meningoencephalomyelitis of unknown origin: 18 cases (2018-2025).” Journal of veterinary internal medicine (2026). PMID: 41742594 ↗
L5OTHERCited in: Pathophysiology, Prognosis and Long-term Outcomes - [106]
Aguilera C, Subah GD, Bogle C et al.. “Utility of Bone Cement for Cranioplasty Following Retrosigmoid or Translabyrinthine Craniectomy: A Systematic Review and Meta-Analysis.” Neurosurgical review (2025). PMID: 41254416 ↗
L2aSR_OBSCited in: History and Physical Examination - [107]
Khan K, Wilson P, Patel MS et al.. “A Systematic Review and Meta-Analysis of Meningitis Risk Reduction After Repair of Spontaneous Lateral Skull Base Cerebrospinal Fluid Leaks.” Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology (2025). PMID: 41039648 ↗
L2aSR_OBSCited in: History and Physical Examination - [108]
Julio PR, Capello CH, de Amorim JC et al.. “Chorea associated with systemic lupus erythematosus- a systematic review.” Lupus (2025). PMID: 40390391 ↗
L2aSR_OBSCited in: History and Physical Examination - [109]
Deniz M, Erat T, Arı HF et al.. “Evaluation of children with acute central nervous system infections admitted to the pediatric intensive care unit and pediatric ward: a retrospective study.” BMC pediatrics (2024). PMID: 39587526 ↗
L2bCOHORTCited in: History and Physical Examination - [110]
Pantalone MR, De Luca F, Terling L et al.. “Candida meningitis in three patients who underwent transsphenoidal surgery from a single-institution case series.” Acta neurochirurgica (2026). PMID: 41826722 ↗
L4CASE_REPORTCited in: History and Physical Examination - [111]
Yuan X, Fang M, Lan W et al.. “From urinary tract infection to deafness: community-acquired meningitis in an adult caused by hypervirulent Klebsiella pneumoniae-a case report.” BMC infectious diseases (2025). PMID: 41390369 ↗
L4CASE_REPORTCited in: History and Physical Examination - [112]
Goh WGW, Ng IKS, Tan MKX et al.. “Clinical Reasoning: A 26-Year-Old Woman With Headache and Eosinophilia.” Neurology (2025). PMID: 39983059 ↗
L4CASE_REPORTCited in: History and Physical Examination - [113]
Willis ZI, Buonsenso D. “Management of Young Infants With Incomplete Evaluation for Meningitis.” Journal of the Pediatric Infectious Diseases Society (2026). PMID: 41670340 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination, Special Populations - [114]
Lovund IK, Mjelle AB, Thaulow CM et al.. “Bacterial Meningitis in Norwegian Children 2010-2023: Low Incidence but Still a Major Threat in Neonates.” Acta paediatrica (Oslo, Norway : 1992) (2026). PMID: 41273196 ↗
L5OTHERCited in: History and Physical Examination - [115]
Krongsut S, Srithanabout P, Pansaksiri S et al.. “A new diagnostic model for the early differentiation of tuberculous and bacterial meningitis to guide timely diagnosis and treatment: Model development and internal validation.” Journal of infection and public health (2025). PMID: 41076850 ↗
L5OTHERCited in: History and Physical Examination - [116]
Nguyen THP, Young BR, Bornstein LM et al.. “Prevalence of Serious Infection Among Hypothermic Young Infants Across Medical Settings.” Hospital pediatrics (2025). PMID: 40947113 ↗
L5OTHERCited in: History and Physical Examination - [117]
Tang R, Mao S, Gu Y et al.. “A Nomogram Model to Predict Meningitis Occurrence in Cerebrospinal Fluid Leak Patients.” The Laryngoscope (2026). PMID: 40923621 ↗
L5OTHERCited in: History and Physical Examination - [118]
Aronson PL, Mahajan P, Meeks HD et al.. “Prediction Rule to Identify Febrile Infants 61-90 Days at Low Risk for Invasive Bacterial Infections.” Pediatrics (2025). PMID: 40854562 ↗
L5OTHERCited in: History and Physical Examination - [119]
Tang Y, Huang P, Xu J et al.. “Comprehensive analysis of disease activity, neuropsychiatric symptoms, imaging features and risk factors for seizure in hospitalized patients with juvenile-onset neuropsychiatric systemic lupus erythematosus.” Seminars in arthritis and rheumatism (2025). PMID: 40784140 ↗
L5OTHERCited in: History and Physical Examination - [120]
Fischer JL, Gallagher TJ, Lin ME et al.. “Complications in Endoscopic Sinus Surgery: A TriNetX Network Analysis.” International forum of allergy & rhinology (2025). PMID: 40782144 ↗
L5OTHERCited in: History and Physical Examination - [121]
Doka Hélène KS, Ignatius E, Berinyuy M et al.. “Nonsurgical Neurological Emergencies in Children: A Cross-Sectional Study of Prevalence, Diagnosis, and Management.” Pediatric neurology (2025). PMID: 40609287 ↗
L5OTHERCited in: History and Physical Examination - [122]
Urmenyi LG, Vinhaes CL, Villalva-Serra K et al.. “Influence of HIV co-infection on clinical presentation and disease outcome in hospitalized adults with tuberculous meningitis in Brazil: a nationwide observational study.” Frontiers in public health (2025). PMID: 40589807 ↗
L5OTHERCited in: History and Physical Examination - [123]
Aronson PL, Mahajan P, Nielsen B et al.. “Risk of Bacterial Infections in Febrile Infants 61 to 90 Days Old With Respiratory Viruses.” Pediatrics (2025). PMID: 40506050 ↗
L5OTHERCited in: History and Physical Examination - [124]
Steele JL, Smith HJ, Takkoush S et al.. “Long-Term Outcomes of Adult Temporal Bone Fractures With Hearing Loss: Results of a Multinational Database Analysis.” The Laryngoscope (2025). PMID: 40202220 ↗
L5OTHERCited in: History and Physical Examination - [125]
Yaeger JP, Hill EL, Ertefaie A et al.. “A Population-Based Study of Rates of Invasive Bacterial Infection (IBI) and Missed IBI in Febrile Infants 8-90 Days of Age.” The Journal of pediatrics (2025). PMID: 40199453 ↗
L5OTHERCited in: History and Physical Examination - [126]
Kameda S, Yamana H, Sasabuchi Y et al.. “Early Corticosteroid Use and Short-Term Outcomes in Pediatric Bacterial Meningitis: A Nationwide Study in Japan, 2014 to 2022.” Pediatric neurology (2025). PMID: 39892022 ↗
L5OTHERCited in: History and Physical Examination - [127]
Liu H, Kong X, Zeng Y et al.. “From pain to meningitis: bacteria hijack nociceptors to promote meningitis.” Frontiers in immunology (2024). PMID: 39877376 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [128]
Yaeger JP, Fiscella KA. “Variability in Invasive Bacterial Infection Proportions Among Febrile Infants Aged 8-90 Days Using Administrative Data.” Academic pediatrics (2025). PMID: 39577560 ↗
L5OTHERCited in: History and Physical Examination - [129]
Chessa E, Congiu F, Rizzo G et al.. “Rationale for investigating the use of anifrolumab in neuropsychiatric systemic lupus erythematosus: a combined narrative and case-based systematic literature review.” Frontiers in immunology (2026). PMID: 41756273 ↗
L2aSR_OBSCited in: Diagnosis and Workup, Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [130]
Nouroozi F, Kazemi HS, Alinezhad A et al.. “Artificial Intelligence-based detection of neuropsychiatric lupus: an exploratory meta-analysis of neuroimaging and multimodal biomarker models.” Clinical and experimental medicine (2026). PMID: 41627551 ↗
L2aSR_OBSCited in: Diagnosis and Workup - [131]
Uawithya E, Siriphiphatcharoen P, Benjapibal B et al.. “Clinical, imaging, and immunological features of GFAP astrocytopathy: a systematic review with regional comparison.” Multiple sclerosis and related disorders (2026). PMID: 41576641 ↗
L2aSR_OBSCited in: Diagnosis and Workup, Differential Diagnosis - [132]
Zhao L, He J, Mei C et al.. “The efficacy of rituximab plus telitacicept in neuropsychiatric systemic lupus erythematosus: A retrospective study.” Clinical immunology (Orlando, Fla.) (2026). PMID: 41708039 ↗
L2bCOHORTCited in: Diagnosis and Workup, Management, Prognosis and Long-term Outcomes - [133]
Wang W, Tang S, Yang J et al.. “Individualized immunotherapy for immune reconstitution-associated cortical encephalitis in an HIV-positive cryptococcal meningitis patient: a case report.” Frontiers in immunology (2026). PMID: 41983125 ↗
L4CASE_REPORTCited in: Diagnosis and Workup, Differential Diagnosis, Management, Prognosis and Long-term Outcomes, Special Populations - [134]
Ogawa T, Yamashiro K, Tsutsumi S et al.. “IgG4-related hypertrophic pachymeningitis presenting with marked dural thickening, widespread white matter changes, and rectus gyrus transdiaphragmatic herniation into the sella turcica: a case report.” Frontiers in immunology (2026). PMID: 41756303 ↗
L4CASE_REPORTCited in: Diagnosis and Workup - [135]
Jain S, Dayal R, Kamal R et al.. “Comparative analysis of diagnostic efficacy of loop-mediated isothermal amplification (LAMP) and CBNAAT in children with suspected tubercular meningitis: a cross-sectional study.” BMJ paediatrics open (2026). PMID: 41850741 ↗
L5OTHERCited in: Diagnosis and Workup - [136]
Gao X, Guo Y, Luo P et al.. “Central nervous system infection caused by Mycoplasma hominis in an adult: a case report and literature review.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2025). PMID: 40788590 ↗
L2aSR_OBSCited in: Differential Diagnosis - [137]
Chaúque BJM, Chagas LB, da Silva TCB et al.. “Promising Drug Repurposing Candidates Targeting Free-Living Amoebae: A Systematic and Critical Review of Laboratory-Based Evidence.” Pathogens (Basel, Switzerland) (2026). PMID: 41901747 ↗
L2aSR_OBSCited in: Differential Diagnosis - [138]
Bogovič P, Kastrin A, Trampuš Bakija A et al.. “Cerebrospinal fluid findings and their temporal pattern in patients with different clinical presentations of tick-borne encephalitis; a cohort study.” Infection (2026). PMID: 41307887 ↗
L2bCOHORTCited in: Differential Diagnosis - [139]
López N, Cuesta G, Puerta-Alcalde P. “Viral meningoencephalitis: a focus on diagnostics.” Current opinion in infectious diseases (2025). PMID: 40990729 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [140]
Di Maria S, Bolcato M, Concato M et al.. “Hospital-Acquired Citrobacter Meningitis Complicated by Pneumocephalus in a Neonate.” Pediatrics (2026). PMID: 41734809 ↗
L4CASE_REPORTCited in: Differential Diagnosis, Supportive Care and Complication Management, Special Populations - [141]
Marín-Cruz I, López-Lobato M, Falcón-Neyra D et al.. “Emergence of Pediatric West Nile Virus Neuroinvasive Disease in Spain: An Expanding Threat in a Changing Climate-A Case Series.” The Pediatric infectious disease journal (2026). PMID: 41361685 ↗
L4CASE_REPORTCited in: Differential Diagnosis, Prognosis and Long-term Outcomes - [142]
Nguyen LCA, Nguyen PMA, Nguyen THN. “Human herpesvirus 7 induced aseptic meningitis in an immunocompetent adult presenting with unusual neurological symptoms: a case report.” Virology journal (2025). PMID: 41299705 ↗
L4CASE_REPORTCited in: Differential Diagnosis, Supportive Care and Complication Management - [143]
Lin Y, Diao Z, Low J et al.. “Therapeutic efficacy of telitacicept in a patient with GFAP autoimmune astrocytopathy: a case report.” Frontiers in immunology (2025). PMID: 41181139 ↗
L4CASE_REPORTCited in: Differential Diagnosis, Prognosis and Long-term Outcomes - [144]
Zhang Y, Zheng S, Li Y et al.. “Case Report: A case of neuropsychiatric lupus with primary central nervous system diffuse large B-cell lymphoma.” Frontiers in immunology (2025). PMID: 40918104 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [145]
Yang J, Zhang F, Guo X et al.. “Human herpesvirus type 4 combined with Brucella abortus meningitis case report.” BMC infectious diseases (2025). PMID: 40855467 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [146]
El-Baba M, Austin E. “Thunderclap headache in a patient with Salmonella Enterica meningitis.” The American journal of emergency medicine (2025). PMID: 40603211 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [147]
Lopez C, Sanchez-Sanchez R, Corona D et al.. “A Fatal Case of Monkeypox-Associated Encephalitis in a Non-HIV-Infected Patient.” Critical care explorations (2025). PMID: 40505032 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [148]
Ramirez J, Furmanek S, Chandler T et al.. “A Ten-Year Retrospective Review of Medical Records of Patients Admitted with Meningitis or Encephalitis at Five Hospitals in the United States Highlights the Potential for Under-Ascertainment of Invasive Meningococcal Disease.” Pathogens (Basel, Switzerland) (2025). PMID: 41156573 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [149]
Shahrivar F, Moghimi A, Hosseinzadeh R et al.. “A comprehensive review on the neurological impact of parasitic infections.” Microbial pathogenesis (2025). PMID: 40446972 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [150]
Pang L, Xu X, Liu Y et al.. “A case report and literature review of neuropsychiatric lupus presenting with coma as the initial symptom.” Medicine (2026). PMID: 41560092 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [151]
Gao P, Chen X, Li Y et al.. “Anti-CASPR2 meningoencephalitis with thickened dura mater induced by various infections: A case report and literature review.” Medicine (2025). PMID: 40550065 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [152]
Veljanoska E, Szende A, McGill F et al.. “Cost implications of introducing the BIOFIRE FILMARRAY meningitis/encephalitis panel vs. real-time PCR in adult and pediatric populations in the UK.” Journal of medical economics (2026). PMID: 41608961 ↗
L5OTHERCited in: Differential Diagnosis - [153]
Yakubovsky M, Kadar L, Katchman E et al.. “Cat scratch disease encephalitis: New insights into rate, clinical features, and long-term outcomes.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41544843 ↗
L5OTHERCited in: Differential Diagnosis, Supportive Care and Complication Management - [154]
Nassur JA, Schnell KM, Dolon CD et al.. “Epidemiology of healthcare-associated ventriculitis and meningitis (HCAVM) and community-acquired meningitis/encephalitis and evaluation of an off-label PCR panel for HCAVM diagnosis.” Microbiology spectrum (2026). PMID: 41451990 ↗
L5OTHERCited in: Differential Diagnosis - [155]
Ellis J, Hale G, Nsangi LJ et al.. “Inpatient initiation of tuberculosis preventive therapy with 1 month of isoniazid and rifapentine for adults with advanced HIV disease and cryptococcal meningitis (IMPROVE): a non-inferiority, randomised controlled trial.” The lancet. HIV (2026). PMID: 41662846 ↗
L1bRCTCited in: Management, Landmark Trials and Key Evidence, Special Populations - [156]
Chandu M, Bhatia R, Modi M et al.. “Patterns and Factors Associated With Cerebral Infarction on MRI in Tuberculous Meningitis: Secondary Analysis of the ACT-TBM Trial.” Stroke (2026). PMID: 41521897 ↗
L1bRCTCited in: Management, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence - [157]
Yuan R, Peng H, Wang Y et al.. “Prognostic nomogram for predicting postoperative meningitis duration in skull base tumor surgery: a retrospective cohort study.” Journal of neurosurgery (2026). PMID: 41349019 ↗
L2bCOHORTCited in: Management, Prognosis and Long-term Outcomes - [158]
Peng H, Yuan R, Zheng Y et al.. “Delayed diagnosis in postoperative bacterial meningitis: A retrospective study in the skull base neoplasm surgery.” Clinical neurology and neurosurgery (2026). PMID: 41317437 ↗
L2bCOHORTCited in: Management - [159]
Smith D, Garikipati R, Bastug K et al.. “Paenibacillus dendritiformis as a Cause of Destructive Meningitis in Infants.” NEJM evidence (2026). PMID: 41632684 ↗
L4CASE_REPORTCited in: Management - [160]
Wang L, Bi Y, Zhou Y et al.. “Meningitis due to pandrug resistant Chryseobacterium gleum: microbiological cure and clinical response with linezolid-based combination therapy.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 41483390 ↗
L4CASE_REPORTCited in: Management, Prognosis and Long-term Outcomes - [161]
Ariza-Varón M, Jaramillo-Arrázola MJ, Riveros L et al.. “Meningitis caused by Fusobacterium nucleatum complicated with cavernous sinus thrombosis: A case report.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41330476 ↗
L4CASE_REPORTCited in: Management, Prognosis and Long-term Outcomes - [162]
Liu W, He T, Qin H et al.. “Concentration of contezolid in cerebrospinal fluid and serum in a patient with renal allograft tuberculosis and tuberculous meningoencephalitis.” BMC infectious diseases (2025). PMID: 41257614 ↗
L4CASE_REPORTCited in: Management - [163]
Maran K, Adams R, Khan A et al.. “Intravenous Liposomal Amphotericin as an Adjunct to Fluconazole in Pediatric Patients With Central Nervous System Coccidioidomycosis: A Single-Center Case Series.” Journal of the Pediatric Infectious Diseases Society (2025). PMID: 41217140 ↗
L4CASE_REPORTCited in: Management, Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [164]
Jiang H, Hu Y, Cai J et al.. “Variations in ventricular distribution of polymyxin B following intraventricular administration in patients with central nervous system infections.” Antimicrobial agents and chemotherapy (2026). PMID: 41196281 ↗
L4CASE_REPORTCited in: Management - [165]
Diop S, Van Caenegem N, Troupel T et al.. “Combination of azathioprine and prednisolone as a treatment for meningoencephalomyelitis of unknown origin in dogs: 54 cases.” Journal of veterinary internal medicine (2026). PMID: 41742501 ↗
L5OTHERCited in: Management, Supportive Care and Complication Management - [166]
Kilgore MD, Carr C, Kuchar M et al.. “Utility of lumbar and external ventricular drainage in the management of meningitis: a systematic review.” Neurosurgical focus (2025). PMID: 41175399 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [167]
Fagundes W, Ahmed AR, Silva YP et al.. “Endoscopic third ventriculostomy versus ventriculoperitoneal shunt for treating pediatric tuberculous meningitis hydrocephalus: a systematic review and meta-analysis.” Journal of neurosurgery. Pediatrics (2025). PMID: 40479834 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [168]
Tang X, Zhang W, Zhou A et al.. “Clinical, imaging, and recurrence analysis of myelin oligodendrocyte glycoprotein antibody-associated disease with initial presentation as meningoencephalitis in children: a single-center retrospective study.” Pediatric radiology (2025). PMID: 40464908 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [169]
Liu L, Wang X, Guo L et al.. “Epidemiological characteristics and disease burden of bacterial meningitis in hospitalized children in China: a 6-year nationwide retrospective study.” BMC infectious diseases (2025). PMID: 40275150 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [170]
Hsu CH, Hsuan YT, Chan YJ et al.. “Clinical presentation of cytomegalovirus meningoencephalitis: a retrospective study of 12 adult patients with a variety of immunocompromised conditions.” BMC infectious diseases (2025). PMID: 40264020 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [171]
Aletayeb SMH, Dehdashtian M, Aramesh MR et al.. “Ten-year review of hospital-acquired neonatal meningitis in a tertiary-level NICU: the important role of acinetobacter species.” BMC infectious diseases (2025). PMID: 40259250 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [172]
Datta A, Vardhan MV, Srivastava C. “Paroxysmal sympathetic hyperactivity in tubercular meningitis: An underacknowledged association.” Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2025). PMID: 41284088 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [173]
Li C, Liu M, Ji Y et al.. “Clinical characteristics and prognostic indicators in Listeria monocytogenes meningoencephalitis: A retrospective case series and literature review.” BMC neurology (2025). PMID: 41087940 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [174]
Sheng C, Wang M, Bao Q et al.. “Anti-tuberculosis therapy combined with ventriculoperitoneal shunt for tuberculous meningitis combined with hydrocephalus: A case report.” Journal of infection and public health (2025). PMID: 40763461 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [175]
Wu C, Han X, Yang F et al.. “Misdiagnosis of autoimmune glial fibrillary acidic protein astrocytopathy as infectious meningitis: a case report.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 40439829 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [176]
Wang X, Liang L, Liang Y et al.. “A rare case of multiple brain abscesses caused by Nocardia abscessus co-infection with tuberculous meningitis in an immunocompetent patient.” BMC infectious diseases (2025). PMID: 40360973 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [177]
Sedgwick AK, Anderson S. “Acute Mastoiditis Complicated by Meningitis: A Case Report and Condition Overview.” Critical care nurse (2025). PMID: 41319997 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [178]
Plaatjie ON, van Furth AMT, Solomons R et al.. “Characterization of CSF tryptophan metabolites in South African children with tuberculous meningitis.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41260406 ↗
L5OTHERCited in: Supportive Care and Complication Management - [179]
Lempinen L, Saat R, Laulajainen-Hongisto A et al.. “Otogenic meningitis in children.” Infection (2026). PMID: 41247662 ↗
L5OTHERCited in: Supportive Care and Complication Management - [180]
Tianrui Y, Lingyun B, Jin G. “Establishment of a risk prediction model for hydrocephalus complicated by neonatal bacterial meningitis.” BMC infectious diseases (2025). PMID: 41013354 ↗
L5OTHERCited in: Supportive Care and Complication Management - [181]
Lin Q, Fang W, Fan K et al.. “A novel diagnostic strategy of differential diagnosis of tuberculous meningitis and non-tuberculous meningitis: a retrospective observational cohort study.” Microbiology spectrum (2026). PMID: 41313026 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [182]
Ashwin JV, Verma R, Shahi MK et al.. “Cognitive impairment in tuberculous meningitis: Systematic review & meta-analysis.” The Indian journal of tuberculosis (2026). PMID: 41831920 ↗
L2aSR_OBSCited in: Prognosis and Long-term Outcomes - [183]
Wang H, Ye S, Sun F. “Comparison of obinutuzumab and rituximab for treating neuropsychiatric lupus: a retrospective case-control study.” Lupus science & medicine (2025). PMID: 41193185 ↗
L3bCASE_CONTROLCited in: Prognosis and Long-term Outcomes - [184]
Walker RS, Vallejos GB, Nurye T et al.. “An analysis of national guidelines for the prevention, diagnosis and treatment of cryptococcal meningitis in sub-Saharan African countries: gaps and opportunities.” BMJ global health (2026). PMID: 41714099 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [185]
Tian C, Jin S, Zhao Z et al.. “Association of Corticosteroid Treatment With Outcomes in Pediatric Patients With Bacterial Meningitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” Clinical therapeutics (2022). PMID: 35272859 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [186]
Hodgson A, Haidara FC, Sow SO et al.. “Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlers.” Vaccine (2025). PMID: 40966979 ↗
L1bRCTCited in: Landmark Trials and Key Evidence, Prevention and Screening - [187]
Calderin JM, Wasserman S, Resendiz-Galvan JE et al.. “Population pharmacokinetics of pyrazinamide and isoniazid in plasma and cerebrospinal fluid from South African adults with tuberculous meningitis.” Antimicrobial agents and chemotherapy (2025). PMID: 40590723 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [188]
Abdelgawad N, Wasserman S, Gausi K et al.. “Population Pharmacokinetics of Rifampicin in Plasma and Cerebrospinal Fluid in Adults With Tuberculosis Meningitis.” The Journal of infectious diseases (2025). PMID: 40295169 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [189]
Samuels THA, Molloy SF, Lawrence DS et al.. “Personalised risk-prediction tools for cryptococcal meningitis mortality to guide treatment stratification in sub-Saharan Africa: a prognostic modelling study based on pooled analysis of two randomised controlled trials.” The Lancet. Global health (2025). PMID: 40288401 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [190]
Diallo F, Haidara FC, Tapia MD et al.. “Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial.” Lancet (London, England) (2025). PMID: 40086461 ↗
L1bRCTCited in: Landmark Trials and Key Evidence, Prevention and Screening - [191]
Chow FC, Kafeero P, Nakimbugwe M et al.. “Safety and Tolerability of a Short Course of Linezolid for the Treatment of Predominantly Moderate to Severe Tuberculous Meningitis in Adults With Human Immunodeficiency Virus.” The Journal of infectious diseases (2025). PMID: 39960851 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [192]
Ibnou Zekri Lassout N, Goyal V, Krantz E et al.. “Bioavailability of a novel sustained-release pellet formulation of 5-flucytosine in healthy-fed participants for use in patients with cryptococcal meningitis.” Clinical and translational science (2024). PMID: 39291723 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [193]
Meya DB, Nalintya E, Skipper CP et al.. “Adjunctive Single-Dose Liposomal Amphotericin to Prevent Cryptococcal Meningitis in People With HIV-Associated Cryptococcal Antigenemia and Low Plasma Cryptococcal Antigen Titers.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39044381 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [194]
Ahmed T, Tauheed I, Hoque S et al.. “A phase 3 non-inferiority trial of locally manufactured Meningococcal ACWY vaccine 'Ingovax ACWY' among Bangladeshi adults.” Vaccine (2024). PMID: 38897895 ↗
L1bRCTCited in: Landmark Trials and Key Evidence, Prevention and Screening - [195]
Asante KP, Mathanga DP, Milligan P et al.. “Feasibility, safety, and impact of the RTS,S/AS01E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.” Lancet (London, England) (2024). PMID: 38583454 ↗
L1bRCTCited in: Landmark Trials and Key Evidence, Prevention and Screening - [196]
Donovan J, Bang ND, Imran D et al.. “Adjunctive Dexamethasone for Tuberculous Meningitis in HIV-Positive Adults.” The New England journal of medicine (2023). PMID: 37819954 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [197]
Boulware DR, Atukunda M, Kagimu E et al.. “Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37606364 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [198]
Haidara FC, Umesi A, Sow SO et al.. “Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia.” The New England journal of medicine (2023). PMID: 37224196 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [199]
Davis AG, Wasserman S, Stek C et al.. “A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus-Associated Tuberculous Meningitis: The LASER-TBM Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36482216 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [200]
Kelentse N, Moyo S, Choga WT et al.. “High concordance in plasma and CSF HIV-1 drug resistance mutations despite high cases of CSF viral escape in individuals with HIV-associated cryptococcal meningitis in Botswana.” The Journal of antimicrobial chemotherapy (2022). PMID: 36322466 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [201]
Jarvis JN, Lawrence DS, Meya DB et al.. “Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.” The New England journal of medicine (2022). PMID: 35320642 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [202]
Paradkar MS, Devaleenal D B, Mvalo T et al.. “Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 35291004 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [203]
Ngan NTT, Thanh Hoang Le N, Vi Vi NN et al.. “An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.” eLife (2021). PMID: 34581270 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [204]
Wasserman S, Davis A, Stek C et al.. “Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial.” Antimicrobial agents and chemotherapy (2021). PMID: 33972248 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [205]
Cresswell FV, Meya DB, Kagimu E et al.. “High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33693537 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [206]
Pett SL, Spyer M, Haddow LJ et al.. “Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status.” AIDS (London, England) (2021). PMID: 33306556 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [207]
Soul JS, Bergin AM, Stopp C et al.. “A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures.” Annals of neurology (2021). PMID: 33201535 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [208]
Dixon S, Ashby S, Kuhne C et al.. “The motor optimality of infants who have had Meningitis in the first months of life: A retrospective study.” Early human development (2026). PMID: 41506216 ↗
L2bCOHORTCited in: Special Populations - [209]
Govender NP, Greene GS, Hullsiek KH et al.. “Effectiveness of a National Reflex Laboratory Cryptococcal Antigen Screening Program for People With Advanced HIV Disease in South Africa: A Nationwide-Sampled Cohort Study (CAST-NET).” Journal of acquired immune deficiency syndromes (1999) (2025). PMID: 40663428 ↗
L2bCOHORTCited in: Special Populations - [210]
Krishnegowda VK, Bandiya P, Nanda D et al.. “Cerebrospinal Procalcitonin for Diagnosing Meningitis in Infants Less Than 90 Days: A Systematic Review and Meta-analysis.” Indian pediatrics (2025). PMID: 41060555 ↗
L2aSR_OBSCited in: Special Populations - [211]
Falconer J, Mmotsa TM, Govender NP et al.. “Diagnosis of cryptococcal meningitis in people living with HIV in low-income countries: barriers and strategies.” Expert review of anti-infective therapy (2025). PMID: 40874873 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [212]
Kitaya S, Otani H, Yanagi M et al.. “Campylobacter fetus meningitis and bacteremia: A case report in a post-liver transplant and post-splenectomy patient and a restructured literature review.” Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2025). PMID: 41241280 ↗
L4CASE_REPORTCited in: Special Populations - [213]
Kay AW, Madison M, Scandrett K et al.. “Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children.” The Cochrane database of systematic reviews (2025). PMID: 41128098 ↗
L2aSR_OBSCited in: Special Populations - [214]
Al Reesi MS, Muttawa LAA, Albolushi MA et al.. “Elizabethkingia Infections - An Important Emerging Cause of Sepsis and Meningitis in Neonates and Infants: Case Series from North Batinah Region, Oman, and literature review.” Sultan Qaboos University medical journal (2025). PMID: 40979593 ↗
L4CASE_REPORTCited in: Special Populations - [215]
Clark D, Barranco-Trabi J, Goo I et al.. “Single-Dose Liposomal Amphotericin Plus Fluconazole and Flucytosine for Cryptococcal Meningitis at a US Public Hospital.” JAMA network open (2026). PMID: 41563759 ↗
L5OTHERCited in: Special Populations - [216]
Mwamba TM, Blasich NP, Coetzee LM et al.. “Cryptococcal antigen titers and semi-quantitative assay scores among people with HIV-associated cryptococcal antigenemia.” Journal of clinical microbiology (2026). PMID: 41537580 ↗
L5OTHERCited in: Special Populations - [217]
Atefi A, Ghanaatpisheh A, Ghasemi A et al.. “Meningitis after COVID-19 vaccination, a systematic review of case reports and case series.” BMC infectious diseases (2024). PMID: 39390499 ↗
L2aSR_OBSCited in: Prevention and Screening - [218]
Ramachandran P, Grose C. “Serious neurological adverse events in immunocompetent children and adolescents caused by viral reactivation in the years following varicella vaccination.” Reviews in medical virology (2024). PMID: 38658176 ↗
L2aSR_OBSCited in: Prevention and Screening - [219]
Taiyeb Khosroshahi M, Hamidi S, Kangari P et al.. “Post-COVID-19 Vaccination Meningitis and Meningoencephalitis: A Systematic Review of Case Series and Case Reports.” The American journal of tropical medicine and hygiene (2025). PMID: 39437771 ↗
L2aSR_OBSCited in: Prevention and Screening - [220]
Tripathi N, Mukherjee S. “Efficacy and Prolonged Safety of Haemophilus influenzae Type b Conjugate Vaccines.” Infectious disorders drug targets (2024). PMID: 38231056 ↗
L2aSR_OBSCited in: Prevention and Screening - [221]
Truong HC, Phan TV, Nguyen HT et al.. “Clinical features and antibiotic resistance in pediatric pneumococcal meningitis in Southern Vietnam, 2012-2023: A multicenter retrospective study.” Journal of infection and public health (2025). PMID: 40318609 ↗
L2bCOHORTCited in: Prevention and Screening - [222]
Asante KP, Bozonnat MC, Savic M et al.. “Incidence rates of malaria, meningitis, and mortality in children younger than 5 years: a prospective cohort study in Ghana and Kenya before the roll-out of the RTS,S/AS01E malaria vaccine from 2016 to 2022.” The Lancet. Global health (2025). PMID: 40288396 ↗
L2bCOHORTCited in: Prevention and Screening - [223]
Bjar N, Hermansson A, Gisselsson-Solen M. “How common is otogenic meningitis? A retrospective study in southern Sweden over 18 years.” Infection (2024). PMID: 38416397 ↗
L2bCOHORTCited in: Prevention and Screening - [224]
Anosike C, Ojiakor IM, Etiaba EI et al.. “Cost-effectiveness and budget impact of malaria, measles, and meningitis vaccines in Africa: a scoping review.” Vaccine (2025). PMID: 41110197 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [225]
Ewing A, Haldeman S, Ratner AJ. “Clinical progress note: Haemophilus influenzae type b.” Journal of hospital medicine (2025). PMID: 40205699 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [226]
Alexander NG, Cutts WD, Hooven TA et al.. “Mechanisms and Manifestations of Group B Streptococcus Meningitis in Newborns.” Journal of the Pediatric Infectious Diseases Society (2025). PMID: 39927629 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [227]
Xu Y, Wang J, Qin X et al.. “Advances in the pathogenesis and treatment of pneumococcal meningitis.” Virulence (2024). PMID: 39192572 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [228]
Gil-Prieto R, Hernandez-Barrera V, Marín-García P et al.. “Hospital burden of pneumococcal disease in Spain (2016-2022): A retrospective study.” Human vaccines & immunotherapeutics (2025). PMID: 39786144 ↗
L2bCOHORTCited in: Prevention and Screening - [229]
Park JJ, Tiefenbach J, Anwar MM et al.. “Estimating the Global and Regional Burden of Streptococcus pneumoniae Meningitis in Children: Protocol for a Systematic Review and Meta-Analysis.” JMIR research protocols (2024). PMID: 39012685 ↗
L2aSR_OBSCited in: Prevention and Screening - [230]
Mikami S, Ishii M, Yano T et al.. “Multifocal meningoencephalitis after vaccination against COVID-19.” Pathology international (2024). PMID: 39570102 ↗
L4CASE_REPORTCited in: Prevention and Screening - [231]
Kim JH, Yoon D, Ko HY et al.. “Risk of encephalitis and meningitis after COVID-19 vaccination in South Korea: a self-controlled case series analysis.” BMC medicine (2024). PMID: 38486297 ↗
L4CASE_REPORTCited in: Prevention and Screening - [232]
Alderson MR, Regan K, Martellet L et al.. “Development of MenFive®, an affordable pentavalent meningococcal conjugate vaccine (ACYWX) for Africa and beyond.” Human vaccines & immunotherapeutics (2025). PMID: 40968077 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [233]
Kato Y, Osada T, Araki N et al.. “Aseptic Meningitis after BNT-162b2 COVID-19 Vaccination: Case Report and Literature Review.” The Keio journal of medicine (2023). PMID: 37743529 ↗
L4CASE_REPORTCited in: Prevention and Screening - [234]
Carnalla-Barajas MN, Soto-Noguerón A, Solórzano-Santos F et al.. “Pneumococcal meningitis in Mexico. Serotype distribution and antimicrobial resistance before and after the introduction of pneumococcal conjugate vaccines in pediatric patients. Results from the GIVEBPVac group.” Journal of infection and public health (2026). PMID: 41223711 ↗
L5OTHERCited in: Prevention and Screening - [235]
Abad R, Navarro C, García-Amil C et al.. “Outbreak of invasive meningococcal disease caused by a meningococcus serogroup B expressing a rare porA genosubtype (19-54, 15), Spain, March to April 2024.” Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin (2025). PMID: 41199706 ↗
L5OTHERCited in: Prevention and Screening - [236]
Kang MS, Lee SH, Jung SI et al.. “Shift from Streptococcus pneumoniae to Klebsiella pneumoniae: a 15-year nationwide study of bacterial meningitis in Korea.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 41076061 ↗
L5OTHERCited in: Prevention and Screening - [237]
Campbell H, Lucidarme J, Clark SA et al.. “Increase in serogroup W invasive meningococcal disease in England associated with pilgrimage to Saudi Arabia, January 2024 to June 2025.” Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin (2025). PMID: 40776896 ↗
L5OTHERCited in: Prevention and Screening - [238]
Lee IG, Lee J, Kim HR et al.. “Galectin-4 potentiates CD8+ T cell immunity by enhancing MHC-I expression on dendritic cells.” Molecular therapy : the journal of the American Society of Gene Therapy (2025). PMID: 40589087 ↗
L5OTHERCited in: Prevention and Screening - [239]
Donovan J, Cresswell FV, Tucker EW et al.. “A clinical practice guideline for tuberculous meningitis.” The Lancet. Infectious diseases (2026). PMID: 40840485 ↗
L1cGUIDELINECited in: Guidelines and Resources - [240]
Malmgren A, Orfanos I, Smedbäck J et al.. “The Swedish Society of Paediatric Infectious Diseases' 2025 Recommendations for the Initial Management of Suspected Paediatric Sepsis With or Without Shock.” Acta paediatrica (Oslo, Norway : 1992) (2025). PMID: 40719519 ↗
L1cGUIDELINECited in: Guidelines and Resources - [241]
Silverstein M, Wong JB, Davis EM et al.. “Screening for Syphilis Infection During Pregnancy: US Preventive Services Task Force Reaffirmation Recommendation Statement.” JAMA (2025). PMID: 40358930 ↗
L1cGUIDELINECited in: Guidelines and Resources - [242]
Chang CC, Harrison TS, Bicanic TA et al.. “Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM.” The Lancet. Infectious diseases (2024). PMID: 38346436 ↗
L1cGUIDELINECited in: Guidelines and Resources - [243]
Cook AM, Morgan Jones G, Hawryluk GWJ et al.. “Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients.” Neurocritical care (2020). PMID: 32227294 ↗
L1cGUIDELINECited in: Guidelines and Resources - [244]
Beier AD, Nikas DC, Assassi N et al.. “Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Closure of Myelomeningocele Within 48 Hours to Decrease Infection Risk.” Neurosurgery (2019). PMID: 31418041 ↗
L1cGUIDELINECited in: Guidelines and Resources - [245]
. “Committee Opinion No. 712: Intrapartum Management of Intraamniotic Infection.” Obstetrics and gynecology (2017). PMID: 28742677 ↗
L1cGUIDELINECited in: Guidelines and Resources - [246]
. “Committee Opinion No. 712 Summary: Intrapartum Management of Intraamniotic Infection.” Obstetrics and gynecology (2017). PMID: 28742671 ↗
L1cGUIDELINECited in: Guidelines and Resources - [247]
Vergnano S, Buttery J, Cailes B et al.. “Neonatal infections: Case definition and guidelines for data collection, analysis, and presentation of immunisation safety data.” Vaccine (2016). PMID: 27491687 ↗
L1cGUIDELINECited in: Guidelines and Resources - [248]
McGill F, Heyderman RS, Michael BD et al.. “The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults.” The Journal of infection (2016). PMID: 26845731 ↗
L1cGUIDELINECited in: Guidelines and Resources - [249]
Bower WA, Hendricks K, Pillai S et al.. “Clinical Framework and Medical Countermeasure Use During an Anthrax Mass-Casualty Incident.” MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports (2015). PMID: 26632963 ↗
L1cGUIDELINECited in: Guidelines and Resources - [250]
Mazzola CA, Choudhri AF, Auguste KI et al.. “Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 2: Management of posthemorrhagic hydrocephalus in premature infants.” Journal of neurosurgery. Pediatrics (2014). PMID: 25988778 ↗
L1cGUIDELINECited in: Guidelines and Resources - [251]
. “Committee Opinion No. 614: Management of pregnant women with presumptive exposure to Listeria monocytogenes.” Obstetrics and gynecology (2014). PMID: 25411758 ↗
L1cGUIDELINECited in: Guidelines and Resources - [252]
Solomon T, Michael BD, Smith PE et al.. “Management of suspected viral encephalitis in adults--Association of British Neurologists and British Infection Association National Guidelines.” The Journal of infection (2012). PMID: 22120595 ↗
L1cGUIDELINECited in: Guidelines and Resources - [253]
Kneen R, Michael BD, Menson E et al.. “Management of suspected viral encephalitis in children - Association of British Neurologists and British Paediatric Allergy, Immunology and Infection Group national guidelines.” The Journal of infection (2012). PMID: 22120594 ↗
L1cGUIDELINECited in: Guidelines and Resources - [254]
. “Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).” MMWR. Morbidity and mortality weekly report (2010). PMID: 20814406 ↗
L1cGUIDELINECited in: Guidelines and Resources - [255]
Bertsias GK, Ioannidis JP, Aringer M et al.. “EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs.” Annals of the rheumatic diseases (2010). PMID: 20724309 ↗
L1cGUIDELINECited in: Guidelines and Resources - [256]
Wright JG, Quinn CP, Shadomy S et al.. “Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.” MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports (2010). PMID: 20651644 ↗
L1cGUIDELINECited in: Guidelines and Resources - [257]
Mygland A, Ljøstad U, Fingerle V et al.. “EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis.” European journal of neurology (2010). PMID: 19930447 ↗
L1cGUIDELINECited in: Guidelines and Resources - [258]
Thwaites G, Fisher M, Hemingway C et al.. “British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children.” The Journal of infection (2009). PMID: 19643501 ↗
L1cGUIDELINECited in: Guidelines and Resources - [259]
Chaudhuri A, Martinez-Martin P, Kennedy PG et al.. “EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults.” European journal of neurology (2008). PMID: 18582342 ↗
L1cGUIDELINECited in: Guidelines and Resources - [260]
Halperin JJ, Shapiro ED, Logigian E et al.. “Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [RETIRED].” Neurology (2007). PMID: 17522387 ↗
L1cGUIDELINECited in: Guidelines and Resources - [261]
. “Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.” Pediatrics (2006). PMID: 16382131 ↗
L1cGUIDELINECited in: Guidelines and Resources - [262]
Rauer S, Kastenbauer S, Dersch R et al.. “Guidelines for diagnosis and treatment in neurology - Lyme neuroborreliosis.” German medical science : GMS e-journal (2025). PMID: 41195425 ↗
L1cGUIDELINECited in: Guidelines and Resources - [263]
Schwarz Chavarri G, Sánchez Hernández C, Moreno Millán N et al.. “[Infectious Disease Prevention Group. Update on vaccines, 2020].” Atencion primaria (2020). PMID: 33388119 ↗
L1cGUIDELINECited in: Guidelines and Resources - [264]
Rauer S, Kastenbauer S, Hofmann H et al.. “Guidelines for diagnosis and treatment in neurology - Lyme neuroborreliosis.” German medical science : GMS e-journal (2020). PMID: 32341686 ↗
L1cGUIDELINECited in: Guidelines and Resources - [265]
Tanaka Y, Kuwana M, Fujii T et al.. “2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases.” Modern rheumatology (2021). PMID: 31903831 ↗
L1cGUIDELINECited in: Guidelines and Resources - [266]
Truffert E, Fournier Charrière E, Treluyer JM et al.. “Guidelines of the French Society of Otorhinolaryngology (SFORL): Nonsteroidal anti-inflammatory drugs (NSAIDs) and pediatric ENT infections. Short version.” European annals of otorhinolaryngology, head and neck diseases (2019). PMID: 31420238 ↗
L1cGUIDELINECited in: Guidelines and Resources - [267]
Risser A, Donovan D, Heintzman J et al.. “NSAID prescribing precautions.” American family physician (2009). PMID: 20000300 ↗
L1cGUIDELINECited in: Guidelines and Resources - [268]
Martins B, Canelas G, Dias R et al.. “[Diagnostic, Therapeutic and Monitoring Approach in Suspected Neurosyphilis: Proposal for a Clinical Guideline].” Acta medica portuguesa (2024). PMID: 39622197 ↗
L1cGUIDELINECited in: Guidelines and Resources - [269]
Guzmán JJ, Duffey MM, Weatherhead J et al.. “Effect of different management strategies on outcomes in subarachnoid neurocysticercosis: a descriptive, multicentre, retrospective cohort study in the USA.” EClinicalMedicine (2026). PMID: 42005930 ↗
L4Cited in: Definition, Synonyms, and Classification - [270]
Maphosa T, Denoeud-Ndam L, Chilikutali L et al.. “Impact of an optimized care model for advanced HIV disease: a non-randomized cluster study in Malawi.” BMC public health (2025). PMID: 40819079 ↗
L2bCited in: Definition, Synonyms, and Classification - [271]
Sun X, Jing R, Zhuang Z et al.. “A nomogram to predict probable meningitis in very preterm and/or very low birth weight infants with early-onset sepsis: a multicenter retrospective study.” BMC pregnancy and childbirth (2026). PMID: 42226150 ↗
L3bCited in: Definition, Synonyms, and Classification - [272]
Snaith AE, van der Putten B, Bril-Keijzers W et al.. “Lineage dynamics of invasive Escherichia coli isolates in the Netherlands from 1975 to 2021: a retrospective longitudinal genomic analysis.” The Lancet. Microbe (2026). PMID: 41864215 ↗
L3bCited in: Definition, Synonyms, and Classification - [273]
de Gier B, Vlaminckx BJM, van Roon A et al.. “Risk of Household Secondary Invasive Group A Streptococcal Infections After a Prophylaxis Policy Change.” JAMA network open (2026). PMID: 41505128 ↗
L4Cited in: Definition, Synonyms, and Classification - [274]
Aizawa Y, Tachikawa J, Ikuse T et al.. “Parechovirus-A3 Infection in Neonates and Young Infants from the Pre-Coronavirus Disease 2019 Pandemic Period to the Post-Restriction Era from the Pediatric Parechovirus Surveillance Group in Japan.” Journal of the Pediatric Infectious Diseases Society (2025). PMID: 41206097 ↗
L3bCited in: Definition, Synonyms, and Classification - [275]
Shinohara K, Tsuda Y, Tsuchido Y et al.. “An 11-year multicentre clinical and genomic surveillance of listeriosis across Japan.” The Journal of infection (2025). PMID: 40684886 ↗
L4Cited in: Definition, Synonyms, and Classification - [276]
Alhan Ö, Koç MM, Batırel A et al.. “Emerging West Nile virus infections in Türkiye.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2025). PMID: 40293623 ↗
L4Cited in: Definition, Synonyms, and Classification - [277]
Briciu V, Ionicǎ AM, Mureşan S et al.. “Experience of a Romanian Lyme Borreliosis Centre in the Multidisciplinary Management of Patients Evaluated for Suspected Lyme Neuroborreliosis.” Microorganisms (2026). PMID: 41753551 ↗
L4Cited in: Definition, Synonyms, and Classification - [278]
Veyrenche N, Boluda S, Pérot P et al.. “One Health Investigation into Fatal Encephalitis Caused by Pigeon Paramyxovirus Type 1, France.” Emerging infectious diseases (2026). PMID: 42116534 ↗
L4Cited in: Definition, Synonyms, and Classification - [279]
Al Safar M, Alguydi HB, Marglani O. “Skull base CSF leak repair in the outpatient Arena: Pushing the boundaries of modern endoscopic surgery.” European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2026). PMID: 41832320 ↗
L4Cited in: Definition, Synonyms, and Classification - [280]
Okethwangu D, Ahirirwe S, Venkateswaran M et al.. “Resilience of health systems in Africa to infectious disease shocks: A qualitative evidence synthesis.” PLOS global public health (2026). PMID: 42566489 ↗
L5Cited in: Definition, Synonyms, and Classification - [281]
Parperis K, Zis P, Evangelou M et al.. “Psychosis in patients with systematic lupus erythematosus: A systematic literature review and meta-analysis.” Lupus (2026). PMID: 41805380 ↗
L1aCited in: Epidemiology and Risk Factors - [282]
Dionisopoulos Z, Sabhaney V, D'Arienzo D et al.. “Prevalence of Invasive Bacterial Infections Among Febrile Infants Aged 60 to 90 Days: A Systematic Review and Meta-Analysis.” JAMA pediatrics (2026). PMID: 42189531 ↗
L2aCited in: Epidemiology and Risk Factors - [283]
Chouksey SS, Jain A, Singh VK et al.. “Unmasking the cognitive burden of adult tuberculous meningitis: A systematic review and meta analysis.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 41629635 ↗
L2aCited in: Epidemiology and Risk Factors - [284]
Magnerou AM, Gams Massi D, Maidawa VP et al.. “HIV-related neurological complications in Cameroon in the era of Test and Treat strategy: prevalence and mortality.” BMC infectious diseases (2026). PMID: 42056892 ↗
L2bCited in: Epidemiology and Risk Factors - [285]
The NT, Lam NX, Luan ND et al.. “Predictors of mortality and clinical outcomes in adult bacterial meningitis in Northern Vietnam: A seven-year cohort analysis.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41864265 ↗
L4Cited in: Epidemiology and Risk Factors - [286]
Luan M, Chen X. “Efficacy and safety of drug therapies for treating tuberculous meningitis: a network meta-analysis.” Journal of infection in developing countries (2026). PMID: 42112729 ↗
L1aCited in: Epidemiology and Risk Factors - [287]
Dutta AK, Dass Hazarika R, Ravikumar KL et al.. “Meningococcal meningitis in India: An expert consensus on use of MCVs.” Human vaccines & immunotherapeutics (2026). PMID: 42446494 ↗
L2aCited in: Epidemiology and Risk Factors - [288]
Wang Y, Dong F, Li C et al.. “Bacterial spectrum and antimicrobial resistance of cerebrospinal fluid pathogens in pediatric bacterial meningitis: a 7-year study in Southwest China with emphasis on post-neurosurgical cases.” Frontiers in cellular and infection microbiology (2026). PMID: 42499543 ↗
L3bCited in: Epidemiology and Risk Factors - [289]
Price M, Farthing S, Wong SH et al.. “Stroke Complicating Pediatric Bacterial Meningitis: A Retrospective Case-Controlled Cohort Analysis.” Pediatric neurology (2026). PMID: 42161222 ↗
L3bCited in: Epidemiology and Risk Factors - [290]
Li H, Li J, Wu Q et al.. “Machine learning-based analysis of prognostic factors in patients with tuberculous meningitis.” BMC infectious diseases (2026). PMID: 41857719 ↗
L3bCited in: Epidemiology and Risk Factors - [291]
Czupryna P, Grygorczuk S, Trojan G et al.. “Clinical characteristics, laboratory findings, and risk factors for severe tick-borne encephalitis (TBE) in northeastern Poland: Analysis of 1654 hospitalized cases between 1993 and 2023.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41850626 ↗
L3bCited in: Epidemiology and Risk Factors - [292]
Ye D, Fei ZT, Wang MJ et al.. “Clinical characteristics of childhood tuberculous meningitis and risk factors for severe neurological sequelae disaggregated by age group.” BMC infectious diseases (2026). PMID: 41639788 ↗
L3bCited in: Epidemiology and Risk Factors - [293]
Ferraris G, Tazzoli S, Folisi C et al.. “Machine Learning to Identify Bacteremia and Meningitis in Febrile Infants: A Systematic Review.” Pediatrics (2026). PMID: 42419745 ↗
L2aCited in: Etiology and Triggering Factors - [294]
Zhang Y, Liang A, Li X et al.. “Cerebrospinal fluid procalcitonin and neutrophil percentage: a combined biomarker for differentiating bacterial from tuberculous meningitis in antibiotic-pretreated patients.” Frontiers in cellular and infection microbiology (2026). PMID: 42416277 ↗
L2bCited in: Etiology and Triggering Factors - [295]
Gadelha Farias LAB, Neto OMV, Sobrinho EPL et al.. “Leptospirosis-associated meningitis in an urban tropical endemic setting in northeastern Brazil: Three New cases and a meta-summary of 176 reported cases.” PLoS neglected tropical diseases (2026). PMID: 42113872 ↗
L4Cited in: Etiology and Triggering Factors - [296]
Szeto CH, Chavez-Morales A, Garza J et al.. “Disseminated Coccidioidomycosis and Coccidioidal Meningitis Hospitalization, Texas, USA, 2016-20231.” Emerging infectious diseases (2026). PMID: 42230324 ↗
L3bCited in: Etiology and Triggering Factors - [297]
Tang CM, Li HC, Su LH et al.. “Pneumococcal meningitis in children and adults before and after implementation of PCV13 into national pediatric immunization program: A cohort study in Taiwan.” Journal of infection and public health (2026). PMID: 42202671 ↗
L4Cited in: Etiology and Triggering Factors - [298]
Jiang H, Wang D, Zhang Q et al.. “Diagnostic accuracy of NGAL and HBP for the diagnosis of acute bacterial meningitis.” Clinica chimica acta; international journal of clinical chemistry (2026). PMID: 42142693 ↗
L3bCited in: Etiology and Triggering Factors - [299]
Nicolau-Guillaumet N, Moutel M, Plouzeau-Jayle C et al.. “Optimized use of the FilmArray Meningitis/Encephalitis panel for early discontinuation of antibiotic therapy.” Microbiology spectrum (2026). PMID: 42089636 ↗
L3bCited in: Etiology and Triggering Factors - [300]
Du H, Tan C, Liu J et al.. “Diagnostic accuracy of serum procalcitonin for intracranial infection in adults: A systematic review and meta-analysis.” Medicine (2026). PMID: 42566625 ↗
L2aCited in: Etiology and Triggering Factors - [301]
Dixit S, Kumar A, Datta A et al.. “Postoperative meningitis in pediatric posterior fossa tumors: risk stratification and the role of early CSF cytology.” Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2026). PMID: 42550272 ↗
L3bCited in: Etiology and Triggering Factors - [302]
Gürler M, Karaoğlu Ç, Yurtcu EE et al.. “Utility and clinical relevance of multiplex PCR panels for diagnosis of central nervous system infections.” The Indian journal of medical research (2026). PMID: 42237827 ↗
L4Cited in: Etiology and Triggering Factors - [303]
Khan AU, Shah SA. “Clinical and laboratory predictors of in hospital mortality in adult bacterial meningitis: A tertiary care study from Pakistan.” Clinical neurology and neurosurgery (2026). PMID: 42097013 ↗
L3bCited in: Etiology and Triggering Factors - [304]
Zhong Q, Bathaiian LS, Liu Y et al.. “Development and validation of a diagnostic nomogram for post-neurosurgical bacterial meningitis.” BMC neurology (2026). PMID: 42067788 ↗
L3bCited in: Etiology and Triggering Factors - [305]
Liu A, Liu Y, Shi L et al.. “Guillain-Barré syndrome following Escherichia coli meningitis after cupping therapy: a case report.” Frontiers in immunology (2026). PMID: 42254014 ↗
L4Cited in: Etiology and Triggering Factors - [306]
Kozák M, Majoros L, Bodnár F et al.. “When the meningitis-encephalitis panel is negative: off-label joint infection PCR detects CTX-M ESBL-producing Proteus mirabilis in adult meningoencephalitis.” BMC infectious diseases (2026). PMID: 42082938 ↗
L4Cited in: Etiology and Triggering Factors - [307]
Abraham A, Linn RL, Flannery DD et al.. “Placental Vascular Pathology Associated with Congenital Lymphocytic Choriomeningitis Virus Infection, Philadelphia, Pennsylvania, USA.” Emerging infectious diseases (2026). PMID: 42066794 ↗
L4Cited in: Etiology and Triggering Factors - [308]
Puppalla P, Farhadi DS, Smetanick D et al.. “Coccidioidomycosis-related hydrocephalus: A case control study.” Medical mycology (2026). PMID: 42500965 ↗
L3bCited in: Etiology and Triggering Factors - [309]
Skipper CP, Dai B, Borges B et al.. “Investigation of human leukocyte antigen alleles as risk factors for cryptococcal disease in Ugandan individuals with HIV.” Human immunology (2026). PMID: 42289175 ↗
L3bCited in: Etiology and Triggering Factors - [310]
Zhang F, Zhao F, Fan C et al.. “Diagnostic value of cerebrospinal fluid antisuprabasin antibody in neuropsychiatric systemic lupus erythematosus.” Lupus science & medicine (2026). PMID: 42562427 ↗
L2bCited in: Pathophysiology - [311]
Donovan J, Thanh NT, Ngoc LHB et al.. “The cause, treatment and outcome of hyponatraemia associated with tuberculous meningitis: An observational study nested within two clinical trials of corticosteroids.” The Journal of infection (2026). PMID: 42167495 ↗
L3bCited in: Pathophysiology - [312]
Garg RK, Kumar N, Suresh V et al.. “Neurocysticercosis-Associated Meningitis: A Systematic Review.” Neurology India (2026). PMID: 42087630 ↗
L4Cited in: Pathophysiology - [313]
Iyer S, Briggs RG, Dallas J et al.. “Coccidioides meningitis as a cause of low-pressure hydrocephalus: A contemporary case series and management strategy.” Clinical neurology and neurosurgery (2026). PMID: 42424789 ↗
L4Cited in: Pathophysiology - [314]
Mayer É, Velay A, Cazorla C et al.. “Tick-borne encephalitis emergence as the third leading cause of encephalitis/meningoencephalitis in western Auvergne-Rhône-Alpes, France.” Infectious diseases now (2026). PMID: 42086146 ↗
L4Cited in: Pathophysiology - [315]
Erdeniz EH, Üdürgücü M, Çoban Y et al.. “Listeria monocytogenes meningitis beyond the neonatal period: a multicenter case series of previously unpublished pediatric cases from Türkiye.” European journal of pediatrics (2026). PMID: 42570017 ↗
L4Cited in: Pathophysiology - [316]
Geng Q, Wang Y, Fan Y et al.. “First reported survival of anthrax meningoencephalitis in a low-incidence region: successful management with mNGS-guided combination therapy.” Frontiers in cellular and infection microbiology (2026). PMID: 42553304 ↗
L4Cited in: Pathophysiology - [317]
Wei W, Jin T, Zhang L et al.. “Case Report: Overlapping multiple sclerosis and neuropsychiatric systemic lupus erythematosus with positive MOG-IgG: a case initially misdiagnosed as depression.” Frontiers in immunology (2026). PMID: 42548805 ↗
L4Cited in: Pathophysiology - [318]
Deng Y, Bao Z, Zhuang S et al.. “Tuberculous meningoencephalitis concurrent with autoimmune glial fibrillary acidic protein astrocytopathy: a case report.” Frontiers in immunology (2026). PMID: 42548599 ↗
L4Cited in: Pathophysiology - [319]
Prasad M, Kumar A, Couban R et al.. “Duration of anti-seizure medicines started for acute symptomatic seizures due to acute meningitis: a systematic review and meta-analysis.” BMC medicine (2026). PMID: 42021346 ↗
L1aCited in: History and Physical Examination - [320]
Charlier C, Vijayaratnam S, Jeanton-Seybel C et al.. “Specificities of pediatric listeriosis beyond the neonatal period: A national prospective study.” Med (New York, N.Y.) (2026). PMID: 41605203 ↗
L4Cited in: History and Physical Examination - [321]
Alrushaydan D, Alsufyani AA, Alhussainan K et al.. “Trans-impedance matrix heatmap patterns in cochlear implant patients with different cochlear pathologies: meningitis, otosclerosis, and temporal bone fractures.” European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2026). PMID: 42026295 ↗
L3bCited in: History and Physical Examination - [322]
Luo Y, Ma M, Tong M et al.. “Machine learning and meningitis prediction in pediatric invasive pneumococcal disease: a retrospective single-center study.” BMC infectious diseases (2026). PMID: 42015065 ↗
L3bCited in: History and Physical Examination - [323]
Player B, Havens PL, Mitchell ML et al.. “Utility of the meningoencephalitis panel in management of neonates with temperature instability.” BMC infectious diseases (2025). PMID: 41430581 ↗
L3bCited in: History and Physical Examination - [324]
Lino GM, Galvão PVM, Magalhães JJF et al.. “Adjunctive linezolid in patients with tuberculous meningitis for the prevention of mortality or neurologic disability: a meta-analysis of randomized controlled trials.” BMC infectious diseases (2026). PMID: 42157129 ↗
L1aCited in: Diagnosis and Workup - [325]
Nasiri MJ, Hamzelouee G, Rezaeinasab M et al.. “A systematic review and meta-analysis of steroid use for treatment of TB meningitis.” The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease (2026). PMID: 42374702 ↗
L2aCited in: Diagnosis and Workup - [326]
Qian MY, He LY, Lan P et al.. “Clinical and neuroimaging predictors of outcome and impact of surgical intervention in cryptococcal meningitis: An observational study.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42361959 ↗
L3bCited in: Diagnosis and Workup - [327]
Wang J, Chae Y, Koo Y et al.. “Platelet-to-lymphocyte ratio as an indicator of idiopathic epilepsy in dogs.” Journal of veterinary internal medicine (2026). PMID: 42207577 ↗
L3bCited in: Diagnosis and Workup - [328]
Luo Y, Guo Y, Liao X et al.. “Post-EV71 vaccination outcomes in meningoencephalitis: no increased clinical severity compared with other enterovirus subtypes in a single-center retrospective study.” Frontiers in cellular and infection microbiology (2026). PMID: 42205485 ↗
L3bCited in: Diagnosis and Workup - [329]
Anderson FE, De Decker S, Bentley RT et al.. “Clinical presentation, prognostic factors, and outcomes of meningoencephalitis of unknown origin in older dogs.” Journal of veterinary internal medicine (2026). PMID: 42117719 ↗
L3bCited in: Diagnosis and Workup - [330]
Chen G, Yu C, Yang Y et al.. “Quantitative mapping of prefrontal oxygenation dysfunction and neuropsychiatric symptoms in patients with systemic lupus erythematosus: a multichannel functional near-infrared spectroscopy study.” Lupus science & medicine (2026). PMID: 42386272 ↗
L3bCited in: Diagnosis and Workup - [331]
Thampy A, Alexander H, John JM et al.. “Early vs. delayed empiric antimicrobial treatment for suspected acute meningitis - a systematic review and meta-analysis.” BMC infectious diseases (2026). PMID: 41688940 ↗
L1aCited in: Supportive Care and Complication Management - [332]
Mahdavi J, Pirayeshfar S, Shariati A et al.. “Fatal brain infection in early life: primary amoebic meningoencephalitis caused by Naegleria fowleri in neonates and infants.” BMC infectious diseases (2026). PMID: 42426619 ↗
L4Cited in: Supportive Care and Complication Management - [333]
Araújo RD, Diniz LMO, Teixeira DC et al.. “Long-Term Outcomes Following Bacterial Meningitis in Childhood: A Systematic Review and Meta-Analysis.” Journal of paediatrics and child health (2026). PMID: 42267426 ↗
L2aCited in: Supportive Care and Complication Management - [334]
Miraclin T A, Rima S, Vanjare HA et al.. “Cryptococcal Choroid Plexitis with Trapped Ventricle in an Immunocompetent Individual: An Autopsy Case with Systematic Review of Reported Cases.” The American journal of tropical medicine and hygiene (2026). PMID: 41916271 ↗
L2aCited in: Supportive Care and Complication Management - [335]
Kapmaz M, Başaran S, Menemenlioğlu D et al.. “The first outbreak of neuroinvasive West Nile virus infection in Istanbul area within 2019.” BMC infectious diseases (2026). PMID: 41826887 ↗
L4Cited in: Supportive Care and Complication Management - [336]
Fayaz M, Khursheed A, Chavda V et al.. “A multivariate prediction model to predict delayed CSF sterilization in paediatric post-meningitic hydrocephalus.” Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2026). PMID: 41917470 ↗
L2bCited in: Supportive Care and Complication Management - [337]
Birbeck GL, Bositis CM, Ume-Ezeoke I et al.. “New onset seizure etiologies and outcomes among adults with HIV in the era of broadly available antiretroviral therapies.” Seizure (2026). PMID: 41830651 ↗
L2bCited in: Supportive Care and Complication Management - [338]
Donovan J, Hung TT, Hiep NTT et al.. “A randomised comparison of management strategies for drug-induced liver injury associated with tuberculous meningitis treatment.” The Journal of infection (2026). PMID: 42309188 ↗
L1bCited in: Prognosis and Long-term Outcomes - [339]
Kumar M, Singh A, Singh R et al.. “Comparison of ethambutol versus streptomycin during the intensive phase in treatment of tuberculous meningitis: an open-label randomized clinical trial.” Postgraduate medical journal (2026). PMID: 41989851 ↗
L1bCited in: Prognosis and Long-term Outcomes - [340]
Grosa DP, Zavadska D, Freimane Z et al.. “Long-Term Outcomes in Adult Patients with Tick-Borne Encephalitis in Latvia.” Pathogens (Basel, Switzerland) (2026). PMID: 42514999 ↗
L2bCited in: Prognosis and Long-term Outcomes - [341]
Younas A, Noor R, Shaukat MT et al.. “Efficacy and Safety of Corticosteroids in Tuberculous Meningitis: Systematic Review, Meta-Analysis, and Meta-Regression.” Brain and behavior (2026). PMID: 42517870 ↗
L1aCited in: Prognosis and Long-term Outcomes - [342]
Mathias S, North K, Santana A et al.. “Efficacy of Antibiotic Regimens for Meningitis in Young Infants Aged 0-59 Days: A Systematic Review.” Pediatrics (2024). PMID: 39087804 ↗
L1aCited in: Landmark Trials and Key Evidence - [343]
Sudo RYU, Câmara MCC, Kieling SV et al.. “Shorter versus longer duration of antibiotic treatment in children with bacterial meningitis: a systematic review and meta-analysis.” European journal of pediatrics (2023). PMID: 37870611 ↗
L1aCited in: Landmark Trials and Key Evidence - [344]
Papachristos DA, Oon S, Hanly JG et al.. “Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review.” Seminars in arthritis and rheumatism (2020). PMID: 33360230 ↗
L1aCited in: Landmark Trials and Key Evidence - [345]
Calderin JM, Resendiz-Galvan JE, Abdelgawad N et al.. “Pharmacokinetics of Dexamethasone in Tuberculous Meningitis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41408415 ↗
L1bCited in: Landmark Trials and Key Evidence - [346]
Bloch J, El Rhali L, Vissing N et al.. “The Spectrum of CNS Infections in Children and Adolescents in Denmark 2017-2023: A Multicenter Population-based Cohort Study.” The Pediatric infectious disease journal (2026). PMID: 41941117 ↗
L3bCited in: Special Populations - [347]
Duffy N, Koirala A, Williams PCM. “Epidemiology and Outcomes of Culture-proven Neonatal Meningitis in Australian Tertiary Hospitals: A Multicenter Retrospective Cohort Study.” The Pediatric infectious disease journal (2026). PMID: 41543078 ↗
L3bCited in: Special Populations - [348]
Hameed TK, Aljarbou TM, Altuwaym AA et al.. “Etiology of invasive bacterial infections in infants 90 days and younger presenting to the emergency department in a children's hospital in Saudi Arabia.” BMC infectious diseases (2026). PMID: 41820864 ↗
L4Cited in: Special Populations - [349]
Aemiro A, Girma A, Setew S et al.. “Prevalence of opportunistic fungal infections (candidiasis and cryptococcal meningitis) among HIV-positive individuals in Ethiopia: A systematic review and meta-analysis (PRISMA compliant).” Medicine (2026). PMID: 42629665 ↗
L2aCited in: Special Populations - [350]
Jiang N, Zhu M, Xiao X et al.. “Clinical characteristics and outcomes of early-onset neonatal bacterial meningitis: a 20-year retrospective comparison of preterm and full-term infants.” BMC pediatrics (2026). PMID: 42661190 ↗
L3bCited in: Special Populations - [351]
Zhang F, Yu Z, Pan J et al.. “Risk factors for acute neurological complications in neonatal bacterial meningitis: a retrospective cohort study.” Jornal de pediatria (2026). PMID: 41864622 ↗
L3bCited in: Special Populations - [352]
Wakutsu T, Inoue E, Nakamoto T et al.. “Recurrent herpes simplex virus type 2 Mollaret meningitis in a man living with HIV: A case report and patient-initiated episodic valacyclovir strategy.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 42031293 ↗
L4Cited in: Special Populations - [353]
Martin NG, Defres S, Willis L et al.. “Paediatric meningitis in the conjugate vaccine era and a novel clinical decision model to predict bacterial aetiology.” The Journal of infection (2024). PMID: 38552719 ↗
L2bCited in: Prevention and Screening - [354]
Fafi I, Cohen R, Levy C et al.. “High Mortality Due to Pneumococcal Meningitis in Children With Sickle Cell Disease: A French Multicenter Observational Study From 2001 to 2021.” The Pediatric infectious disease journal (2025). PMID: 40063777 ↗
L4Cited in: Prevention and Screening - [355]
Mahtab S, Madewell ZJ, Baillie V et al.. “Etiologies and comorbidities of meningitis deaths in children under 5 years in high-mortality settings: Insights from the CHAMPS Network in the post-pneumococcal vaccine era.” The Journal of infection (2024). PMID: 39521254 ↗
L3bCited in: Prevention and Screening - [356]
Cooper LV, Djedanem M, Nasser AA et al.. “Effectiveness of NmCV-5 vaccine against meningococcal meningitis in an outbreak setting in Niger: results from a case-control study.” Vaccine (2026). PMID: 42585809 ↗
L4Cited in: Prevention and Screening - [357]
Diallo MB, Youa IF, Wann A et al.. “Trends in bacterial meningitis in Guinea in the post-MenAfriVac era: a retrospective cross-sectional study (2021-2024).” BMC infectious diseases (2026). PMID: 41667987 ↗
L3bCited in: Prevention and Screening - [358]
Garcia-Carretero R, Gil-Prieto R, Hernandez-Barrera V et al.. “Epidemiological and clinical impact of pneumococcal disease in Spain in 2023: A nationwide retrospective analysis.” Human vaccines & immunotherapeutics (2025). PMID: 41207664 ↗
L3bCited in: Prevention and Screening - [359]
Groenveld MA, Visser DH, Brouwer MC et al.. “Clinical characteristics, outcomes and molecular epidemiology of group B streptococcal disease in young infants in the Netherlands.” The Journal of infection (2026). PMID: 42471216 ↗
L2bCited in: Epidemiology and Risk Factors - [360]
Kriz L, Schreiner B, Kana V et al.. “Noninfectious meningitis related to nusinersen: a pharmacovigilance analysis using the WHO database.” Neuromuscular disorders : NMD (2026). PMID: 42727322 ↗
L3bCited in: Epidemiology and Risk Factors - [361]
Tasaki K, Hara M, Shiota H et al.. “FilmArray Meningitis/Encephalitis Panel accelerates central nervous system infection diagnosis and reduces empirical acyclovir use: A Japanese prospective study.” Journal of infection and public health (2026). PMID: 42679643 ↗
L2bCited in: Pathophysiology - [362]
Wang H, Huang M, Song J et al.. “Etiologic diagnosis of suspected tuberculous meningitis by multiplex PCR of cerebrospinal fluid.” Journal of clinical microbiology (2026). PMID: 42623488 ↗
L2bCited in: Pathophysiology - [363]
Chiappe Gonzalez A, Gómez de la Torre JC, Montenegro-Idrogo JJ et al.. “Enhancing meningitis diagnosis: a diagnostic stewardship workflow in a resource-limited setting.” Microbiology spectrum (2026). PMID: 42549913 ↗
L2bCited in: Pathophysiology - [364]
Liao Y, Lv F, Quan T et al.. “Contezolid in tuberculous meningitis: comparable efficacy and favorable safety.” Frontiers in cellular and infection microbiology (2026). PMID: 42774160 ↗
L4Cited in: Pathophysiology - [365]
Guo F, Kang L, Li B et al.. “Aseptic meningitis and meningoencephalitis associated with pediatric histiocytic necrotizing lymphadenitis: a 26-case series.” Frontiers in immunology (2026). PMID: 42688186 ↗
L4Cited in: Pathophysiology - [366]
Lee YH, Seok H, Chung DR et al.. “Clinical characteristics of possible Mycoplasma pneumoniae-associated meningoencephalitis in adults.” Journal of infection and public health (2026). PMID: 42624009 ↗
L4Cited in: Pathophysiology - [367]
Shi P, Liu Z, Wu X et al.. “Clinical utility of CSF metagenomic next-generation sequencing in suspected CNS infection: performance against a composite reference standard and read-count stratification.” Frontiers in cellular and infection microbiology (2026). PMID: 42582033 ↗
L3bCited in: Pathophysiology - [368]
Zheng G, Zhao S, Mi D et al.. “Machine learning models for predicting cerebrospinal fluid bacterial culture outcomes in post-neurosurgical meningitis-development and temporal three-year validation.” Archives of microbiology (2026). PMID: 42799883 ↗
L3bCited in: Pathophysiology - [369]
Vasilyeva I, Klevno N, Kazakov A et al.. “Tuberculous Meningitis in Pediatric Patients: Diagnosis, Clinical Course, and Outcomes in the Modern Era.” Pathogens (Basel, Switzerland) (2026). PMID: 42796696 ↗
L4Cited in: Pathophysiology - [370]
Kuntal K, Singh M, Jain P et al.. “Drug resistance in tuberculous meningitis: A laboratory-based observational study from Northern India's tertiary care referral centre.” Tuberculosis (Edinburgh, Scotland) (2026). PMID: 42537574 ↗
L3bCited in: Pathophysiology - [371]
Pinos Garcia YI, Rosas C, Elmohrez JE et al.. “Chlamydia psittaci Meningitis, Chile, 2023.” Emerging infectious diseases (2026). PMID: 42811471 ↗
L4Cited in: Pathophysiology - [372]
Ahmad M, Umair M, Akram MZ. “Acute ischemic stroke revealing cryptococcal meningitis in an HIV-infected patient with a relatively preserved CD4 count: a case report.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 42678554 ↗
L4Cited in: Pathophysiology - [373]
Kalita J, Nizami FM, Pandey PC et al.. “Status epilepticus in scrub typhus versus tuberculous meningitis: A comparative study.” Epilepsy research (2026). PMID: 41558069 ↗
L2bCited in: History and Physical Examination - [374]
Tavares MP, Pauna HF, Monsanto RDC et al.. “Greater Cochlear Damage in Otogenic Versus Meningogenic Meningitis: Hearing Rehabilitation Implications.” The Laryngoscope (2026). PMID: 41949031 ↗
L3bCited in: History and Physical Examination - [375]
Zeng W, Xiao X, Liu Q et al.. “PPD skin test positivity and in-hospital mortality across age groups in non-HIV tuberculous meningitis: a retrospective cohort study.” Frontiers in neurology (2026). PMID: 42666175 ↗
L3bCited in: Diagnosis and Workup - [376]
Groenveld MA, Miselli F, Creti R et al.. “Neonatal sepsis and meningitis caused by Group B Streptococcus or Escherichia coli in twins. A systematic review.” The Journal of infection (2026). PMID: 42497927 ↗
L2aCited in: Special Populations - [377]
Graham EE, Tetens MM, Bodilsen J et al.. “Academic achievements after childhood meningitis: a nationwide, population-based cohort study.” Infectious diseases (London, England) (2026). PMID: 42189848 ↗
L4Cited in: Special Populations - [378]
Jansen ML, van Kempen EB, Tulling AJ et al.. “The Severity and Characteristics of Pediatric Group A Streptococcal Meningitis in the Netherlands (2015-June 2024): Results From a Nationwide Multicenter Cohort Study.” The Pediatric infectious disease journal (2026). PMID: 41986932 ↗
L4Cited in: Special Populations